<SEC-DOCUMENT>0001213900-24-050097.txt : 20240605
<SEC-HEADER>0001213900-24-050097.hdr.sgml : 20240605
<ACCEPTANCE-DATETIME>20240605170226
ACCESSION NUMBER:		0001213900-24-050097
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20240605
FILED AS OF DATE:		20240605
DATE AS OF CHANGE:		20240605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MDxHealth SA
		CENTRAL INDEX KEY:			0001872529
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C9

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40996
		FILM NUMBER:		241022825

	BUSINESS ADDRESS:	
		STREET 1:		CAP BUSINESS CENTER
		STREET 2:		RUE D'ABHOOZ, 31, B-4040
		CITY:			HERSTAL
		STATE:			C9
		ZIP:			00000
		BUSINESS PHONE:		949-271-9221

	MAIL ADDRESS:	
		STREET 1:		CAP BUSINESS CENTER
		STREET 2:		RUE D'ABHOOZ, 31, B-4040
		CITY:			HERSTAL
		STATE:			C9
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MDx Health SA
		DATE OF NAME CHANGE:	20210713
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0207370-6k_mdxhealth.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16<BR>
UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the month of June 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number 001-40996</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MDXHEALTH SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CAP Business Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Zone Industrielle des Hauts-Sarts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">4040 Herstal, Belgium</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">+32 4 257 70 21</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MDXHEALTH SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">MDxHealth SA (the &ldquo;Company&rdquo;) held
its ordinary annual general shareholders&rsquo; meeting (&ldquo;AGM&rdquo;) and an extraordinary general shareholders&rsquo; meeting
(&ldquo;EGM&rdquo;) on Thursday, May 30, 2024. The items on the agenda of the AGM included the approval of a number of resolutions
relating to the financial year ended on December 31, 2023, as well as the renewal of board mandates and approval of director
remuneration. There was no attendance quorum for the AGM, and the proposed resolutions that were submitted to the meeting were all
duly passed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">As the required attendance quorum
for the EGM was not met, a new EGM will be held on Thursday, June 20, 2024 at 3:00 p.m., Belgian time, at the offices of the notary public
Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There
will be no attendance quorum for this second EGM. The Company hereby furnishes the attached documents in connection with this second EGM.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white"><I>The information
in the attached Exhibits 99.1-99.10 is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that Section,
nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or
the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify; width: 9%"><B>Exhibit No.</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: justify; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify; width: 90%"><B>Description of Exhibit</B></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">99.1</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea020737001ex99-1_mdxhealth.htm">Convening Notice</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">99.2</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea020737001ex99-2_mdxhealth.htm">Extraordinary General Shareholders&rsquo; Meeting Notice Letter</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">99.3</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea020737001ex99-3_mdxhealth.htm">Attendance Form</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">99.4</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea020737001ex99-4_mdxhealth.htm">Proxy Form</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">99.5</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1872529/000121390024043996/ea020616001ex99-7_mdxhealth.htm">Board Report in relation to the 2024 Share Option Plan (Incorporated by Reference to Exhibit 99.7 to the Company&rsquo;s Current Report on Form 6-K filed with the Commission on May 16, 2024)</A>.</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">99.6</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1872529/000121390024043996/ea020616001ex99-8_mdxhealth.htm">2024 Share Option Plan (Incorporated by Reference to Exhibit 99.8 to the Company&rsquo;s Current Report on Form 6-K filed with the Commission on May 16, 2024).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">99.7</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1872529/000121390024043996/ea020616001ex99-9_mdxhealth.htm">Board Report in relation to the Exact Sciences Warrants (Incorporated by Reference to Exhibit 99.9 to the Company&rsquo;s Current Report on Form 6-K filed with the Commission on May 16, 2024).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">99.8</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1872529/000121390024043996/ea020616001ex99-10_mdxhealth.htm">Exact Sciences Warrants Terms &amp; Conditions (Incorporated by Reference to Exhibit 99.10 to the Company&rsquo;s Current Report on Form 6-K filed with the Commission on May 16, 2024).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">99.9</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1872529/000121390024043996/ea020616001ex99-11_mdxhealth.htm">Board Report in relation to the OrbiMed Warrants (Incorporated by Reference to Exhibit 99.11 to the Company&rsquo;s Current Report on Form 6-K filed with the Commission on May 16, 2024).</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">99.10</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1872529/000121390024043996/ea020616001ex99-12_mdxhealth.htm">OrbiMed Warrants Terms &amp; Conditions (Incorporated by Reference to Exhibit 99.12 to the Company&rsquo;s Current Report on Form 6-K filed with the Commission on May 16, 2024).</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><B>MDXHEALTH SA</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: June 5, 2024</TD>
    <TD>By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid">/s/ Michael McGarrity</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 31%">Michael McGarrity</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea020737001ex99-1_mdxhealth.htm
<DESCRIPTION>CONVENING NOTICE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation &ndash; For informational
purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MDxHealth SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Limited Liability Company<BR>
(<I>soci&eacute;t&eacute; anonyme)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CAP Business Center<BR>
Zone Industrielle des Hauts-Sarts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rue d&rsquo;Abhooz 31<BR>
4040 Herstal, Belgium<BR>
VAT BE 0479.292.440 (RLP Li&egrave;ge, division Li&egrave;ge)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<DIV STYLE="border: Black 1.5pt solid; padding: 1pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INVITATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>extraordinary
G</B></FONT><B>ENERAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">to be held on Thursday, 20 June 2024, at 3:00 p.m.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As the quorum for the deliberation and voting
on the matters on the agenda of the extraordinary general meeting of MDxHealth SA (the &ldquo;<B>Company</B>&rdquo;) held on 30 May 2024
was not reached, the holders of securities of the Company are invited to attend a second extraordinary general shareholders&rsquo; meeting of
the Company before the notary public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Date, hour and venue:</B> The extraordinary
general shareholders&rsquo; meeting will be held on Thursday, 20 June 2024 at 3:00 p.m. at the offices of the notary public Stijn Raes, at Kortrijksesteenweg
1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opening of the doors:</B> In order to facilitate
the keeping of the attendance list on the day of the extraordinary general shareholders&rsquo; meeting, holders of securities and their representatives
are invited to register as of 2:15 p.m.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>extraordinary</B></FONT><B>
GENERAL MEETING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Agenda and proposed resolutions: </B>The agenda
and proposed resolutions of the extraordinary general shareholders&rsquo; meeting of the Company which, as the case may be, can be amended at
the meeting on behalf of the board of directors, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Submission of reports - 2024 Share Option Plan </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Submission of and discussion on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the report of the board of directors of the Company, prepared in accordance with articles 7:180 and 7:191
of the Belgian Companies and Associations Code, in relation to the proposal to issue 2,000,000 new subscription rights for shares of the
Company (the &ldquo;<B>2024 Share Options</B>&rdquo;), pursuant to a share option plan named &ldquo;the 2024 Share Option Plan&rdquo;, and
to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar
as required, of the holders of outstanding subscription rights (share options) of the Company, for the benefit of the members of the personnel
of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian Companies and Associations Code
(the &ldquo;<B>Selected Participant</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the report of the statutory auditor of the Company, prepared in accordance with articles 7:180 and 7:191
of the Belgian Companies and Associations Code, in relation to the proposal to issue 2,000,000 2024 Share Options, and to dis-apply, in
the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required,
of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.5in"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Proposal to issue 2,000,000 2024 Share Options </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Proposed resolution: </I>The general
shareholders&rsquo; meeting resolves to approve the issuance of 2,000,000 2024 Share Options, pursuant to a share option plan named the &ldquo;2024
Share Option Plan&rdquo;, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders
of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, for the benefit
of Selected Participant. In view thereof, the general shareholders&rsquo; meeting resolves as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Terms and conditions of the 2024 Share Options</U>: The terms and conditions of the 2024 Share Options
(including, but not limited to, the exercise price of the 2024 Share Options) shall be as set out in the annex to the report of the board
of directors referred to in item 1.(a) of the agenda (for the purpose of this resolution, the &ldquo;<B>Plan</B>&rdquo;), a copy of which
shall remain attached to the minutes recording the present resolution. The 2024 Share Options have a term of ten years as from their issue
date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Underlying shares</U>: Each 2024 Share Option shall entitle the holder thereof to subscribe for one
new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2024 Share Options shall have
the same rights and benefits as, and rank <I>pari passu</I> in all respects, including as to entitlements to dividends and other distributions,
with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions
in respect of which the relevant record date or due date falls on or after the date of issue of the new shares.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Dis-application of the preferential subscription right for the benefit of the Selected Participants</U>:
The general shareholders&rsquo; meeting resolves, in accordance with article 7:191 of the Belgian Companies and Associations Code, to dis-apply,
in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required,
of the holders of outstanding subscription rights (share options) of the Company, for the benefit of the Selected Participants, and to
approve the possibility for the Company to grant the 2024 Share Options to the Selected Participants, as further explained in the report
of the board of directors referred to in item 1.(a) of the agenda and the terms and conditions of the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Confirmation of the subscription of 2024 Share Options by the Company</U>: The general shareholders&rsquo;
meeting resolves to approve and confirm that the Company will be able to subscribe for the 2024 Share Options, with a view to creating
a pool of outstanding 2024 Share Options available for further grants to Selected Participants. The Company may not, however, exercise
the 2024 Share Options for its own account.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Conditional capital increase and issue of new shares</U>: The general shareholders&rsquo; meeting resolves,
subject to, and to the extent of the exercise of the 2024 Share Options, to increase the Company&rsquo;s share capital and to issue the relevant
number of new shares issuable upon the exercise of the 2024 Share Options. Subject to, and in accordance with, the provisions of the Plan,
upon exercise of the 2024 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2024 Share Options
will be allocated to (as the case may be, following conversion into the Company&rsquo;s share capital currency, on the basis of the relevant
USD/EUR exchange ratio as shall be published by the European Central Bank, as provided for in section 5.2 of the Plan) the share capital
of the Company. To the extent that the amount of the exercise price of the 2024 Share Options, per share to be issued upon exercise of
the 2024 Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue
of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2024 Share Options, equal to such
fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase
and issuance of new shares, each new and existing share shall represent the same fraction of the share capital of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Issue premium</U>: Any issue premium that will be booked in connection with the 2024 Share Options
shall be accounted for on a non-distributable account on the liabilities side of the Company&rsquo;s balance sheet under its net equity, and
the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only
be reduced on the basis of a lawful resolution of the general shareholders&rsquo; meeting passed in the manner required for an amendments to
the Company&rsquo;s articles of association.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -36.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD STYLE="text-align: justify"><U>Powers of attorney</U>: The board of directors is authorised to implement and execute the resolutions
passed by the general shareholders&rsquo; meeting in connection with the 2024 Share Options, and to take all steps and carry out all formalities
that shall be required by virtue of the Plan, the Company&rsquo;s articles of association and applicable law in order to issue or transfer the
shares upon exercise of the 2024 Share Options. Furthermore, each of the Company&rsquo;s directors, Joe Sollee and Ron Kalfus, each such person
acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2024
Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B)
the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company&rsquo;s articles of association
in order to reflect the new share capital and number of outstanding shares following the exercise of the 2024 Share Options, (ii) to sign
and deliver, on behalf of the Company, the relevant Euroclear, Computershare, Nasdaq, bank and/or other documentation, the share register
and all other necessary documents in connection with the issuance and delivery of the shares to the Selected Participants concerned and
the admission to listing and trading of such shares, and (iii) to do whatever may be necessary or useful (including but not limited to
the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2024 Share Options
to trading on Nasdaq (or such other markets on which the Company&rsquo;s shares will be trading at that time).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Submission of reports &ndash; Exact Sciences Warrants</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Submission of and discussion on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the report of the board of directors of the Company, prepared in accordance with articles 7:180, 7:191
and 7:193 of the Belgian Companies and Associations Code, in relation to the proposal to issue, for the benefit of Genomic Health, Inc.
(a subsidiary of Exact Sciences Corporation referred to herein as &ldquo;<B>Exact Sciences</B>&rdquo;) 1,000,000 new subscription rights
for shares of the Company (the <B>&ldquo;Exact Sciences Warrants&rdquo;</B>), and to dis-apply, in the interest of the Company, the preferential
subscription right of the Company&rsquo;s existing shareholders and, insofar as required, of the holders of subscription rights (share options)
of the Company, for the benefit of Exact Sciences; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the report of the Company&rsquo;s statutory auditor, prepared in accordance with articles 7:180, 7:191 and 7:193
of the Belgian Companies and Associations Code, in relation to the proposal to issue for the benefit of Exact Sciences 1,000,000 Exact
Sciences Warrants, and to dis-apply, in the interest of the Company, the preferential subscription right of the Company&rsquo;s existing shareholders
and, insofar as required, of the holders of subscription rights (share options) of the Company, for the benefit of Exact Sciences.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Proposal to issue 1,000,000 Exact Sciences Warrants</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I><U>Proposed resolution</U>:</I> The
general shareholders&rsquo; meeting resolves to approve the issuance of 1,000,000 new subscription rights for shares of the Company, called
the &ldquo;Exact Sciences Warrants&rdquo;, and to dis-apply, in the interest of the Company, the preferential subscription right of the
Company&rsquo;s existing shareholders and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company,
for the benefit of Exact Sciences. To this end, the general shareholders&rsquo; meeting resolves as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Terms and conditions of the subscription rights</U>: The terms and conditions of the Exact Sciences
Warrants will be in accordance with Annex A of the report of the board of directors referred to in item 3.(a) of the agenda (for the purposes
of this resolution, the &ldquo;<B>Exact Sciences Warrants Terms and Conditions</B>&rdquo;), a copy of which will remain attached to the
minutes recording the present resolution. The main terms and conditions of the Exact Sciences Warrants can, for information purposes,
be summarised as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><I>Right to subscribe for one ordinary share</I>: Each Exact Sciences Warrant entitles the holder to subscribe
for one (1) ordinary share of the Company to be issued by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><I>Exercise price</I>: The exercise price of the Exact Sciences Warrants <FONT STYLE="background-color: white">(i.e.,
the price to be paid in cash to subscribe for one new share in the Company when an Exact Sciences Warrant is exercised) </FONT>will be
USD&nbsp;5.265. The exercise price is subject to potential customary downward adjustments in the case of certain dilutive actions of the
Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify"><I>Term: </I>The Exact Sciences Warrants will have a term starting as from their issuance and ending on
(and including) August 22, 2028.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify"><I>Exercisability:</I> The exercise of the Exact Sciences Warrants will be subject to the terms and conditions
contained in the Exact Sciences Warrants Terms and Conditions. The Exact Sciences Warrants may be exercised as from their issuance and
until the end of their term, provided that a number of Exact Sciences Warrants with an aggregate exercise price of at least USD&nbsp;250,000
are exercised by the holder thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify"><I>Transferability:</I> Except if the Company were to explicitly allow a transfer of the Exact Sciences
Warrants, the Exact Sciences Warrants cannot be transferred by the holder. Furthermore, the Exact Sciences Warrants will not be admitted
to listing or trading.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Underlying shares</U>: Each Exact Sciences Warrant will entitle its holder to subscribe for one new
share to be issued by the Company. The new shares to be issued upon exercise of the Exact Sciences Warrants shall have the same rights
and benefits as, and rank <I>pari passu</I> in all respects including as to entitlement to dividends and other distributions, with the
existing and outstanding shares of the Company at the moment of their issuance and will be entitled to dividends and other distributions
in respect of which the relevant record date or due date falls on or after the date of their issuance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Dis-application of the preferential subscription right for the benefit of Exact Sciences</U>: The general
shareholders&rsquo; meeting resolves, in accordance with articles 7:191 and 7:193 of the Belgian Companies and Associations Code, to dis-apply,
in the interest of the Company, the preferential subscription right of existing shareholders of the Company and, insofar as required,
of the holders of subscription rights (share options) of the Company, for the benefit of Exact Sciences, as explained in the report of
the board of directors referred to in item 3.(a) of the agenda.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Conditional capital increase and issue of new shares</U>: The general shareholders&rsquo; meeting resolves,
subject to and in the case of the exercise of the Exact Sciences Warrants, to increase the share capital of the Company and to issue the
appropriate number of new shares that may be issued upon exercise of the Exact Sciences Warrants. Subject to, and in accordance with,
the respective provisions of the Exact Sciences Warrants Terms and Conditions, upon exercise of the Exact Sciences Warrants and the issuance
of new shares, the aggregate amount of the exercise price of the Exact Sciences Warrants <FONT STYLE="background-color: white">will be
allocated to (as the case may be, following conversion into the Company&rsquo;s share capital currency, on the basis of the relevant USD/EUR
exchange ratio as shall be published by the European Central Bank, as provided for in section 5.4 of the Exact Sciences Warrants Terms
and Conditions) the share capital of the Company</FONT>. To the extent that the amount of the exercise price of the Exact Sciences Warrants,
per share to be issued upon exercise of the Exact Sciences Warrants, exceeds the fractional value of the then existing shares of the Company
existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise
of the Exact Sciences Warrants, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as
issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction
of the share capital of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Issue premium</U>: Any issue premium that will be booked in connection with the Exact Sciences Warrants
(whether upon exercise of the Exact Sciences Warrants, or otherwise) will be accounted for on a non-distributable account on the liabilities
side of the Company&rsquo;s balance sheet under its net equity, and the account on which the issue premium will be booked shall, like the share
capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general shareholders&rsquo;
meeting passed in the manner required for an amendments to the Company&rsquo;s articles of association.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Powers of attorney</U>: The board of directors is authorised to implement and execute the resolutions
adopted by the general shareholders&rsquo; meeting in connection with the Exact Sciences Warrants, and to take all measures and carry out all
formalities that will be required pursuant to the Exact Sciences Warrants Terms and Conditions, the Company&rsquo;s articles of association
and all applicable laws in order to issue or transfer the shares upon exercise of the Exact Sciences Warrants. In addition, each director
of the Company, Joe Sollee and Ron Kalfus, each such person acting individually and with the possibility of sub-delegation and power of
subrogation, shall have the power, upon exercise of the Exact Sciences Warrants, (i) to proceed with the recording of (A) the capital
increase and the issue of new shares resulting from such exercise, (B) the allocation as share capital and (if applicable) as issue premium,
and (C) the amendment of the Company&rsquo;s articles of association to reflect the new share capital and number of shares outstanding following
the exercise of the Exact Sciences Warrants (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Computershare,
Nasdaq and/or bank documentation, the share register and all other necessary documents in connection with the issuance and delivery of
the shares to the beneficiary and the admission to listing and trading of such shares, and (iii) to do whatever may be necessary or useful
(including, but not limited to, the preparation and execution of all documents and forms) for the admission of the shares issued upon
exercise of the Exact Sciences Warrants to trading on Nasdaq (or any other market on which the Company&rsquo;s shares will then be traded).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Submission of reports &ndash; OrbiMed Warrants </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">Submission of and discussion on:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">the report of the board of directors of the Company, prepared in accordance with articles 7:180, 7:191
and 7:193 of the Belgian Companies and Associations Code, in relation to the proposal to issue, for the benefit of OrbiMed Royalty &amp;
Credit Opportunities IV, LP and OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP (together referred to herein as &ldquo;<B>OrbiMed</B>&rdquo;)
1,243,060 new subscription rights for shares of the Company (of those 1,243,060 new subscription rights for shares, 881,906 new subscription
rights for shares to be issued for the benefit of OrbiMed Royalty &amp; Credit Opportunities IV, LP and 361,154 new subscription rights
for shares to be issued for the benefit of OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP), with a term of 5 years as from
their issue date (the &ldquo;<B>OrbiMed Warrants</B>&rdquo;), and to dis-apply, in the interest of the Company, the preferential subscription
right of the Company&rsquo;s existing shareholders and, insofar as required, of the holders of subscription rights (share options) of the Company,
for the benefit of OrbiMed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">the report of the Company&rsquo;s statutory auditor, prepared in accordance with articles 7:180, 7:191 and 7:193
of the Belgian Companies and Associations Code, in relation to the proposal to issue for the benefit of OrbiMed 1,243,060 OrbiMed Warrants,
and to dis-apply, in the interest of the Company, the preferential subscription right of the Company&rsquo;s existing shareholders and, insofar
as required, of the holders of subscription rights (share options) of the Company, for the benefit of OrbiMed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 35.45pt"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Proposal to issue 1,243,060 OrbiMed Warrants</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I><U>Proposed resolution</U>:</I> The
general shareholders&rsquo; meeting resolves to approve the issuance of 1,243,060 new subscription rights for shares of the Company, with a
term of 5 years as from their issue date, called the &ldquo;OrbiMed Warrants&rdquo;, and to dis-apply, in the interest of the Company, the
preferential subscription right of the Company&rsquo;s existing shareholders and, insofar as required, of the holders of subscription rights
(share options) of the Company, for the benefit of each of OrbiMed Royalty &amp; Credit Opportunities IV, LP and OrbiMed Royalty &amp;
Credit Opportunities IV Offshore, LP. To this end, the general shareholders&rsquo; meeting resolves as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><U>Terms and conditions of the subscription rights</U>: The terms and conditions of the OrbiMed Warrants
will be in accordance with Annex A of the report of the board of directors referred to in item 5.(a) of the agenda (for the purposes of
this resolution, the &ldquo;<B>OrbiMed Warrants Terms and Conditions</B>&rdquo;), a copy of which will remain attached to the minutes recording
the present resolution. The main terms and conditions of the OrbiMed Warrants can, for information purposes, be summarised as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><I>Right to subscribe for one ordinary share</I>: Each OrbiMed Warrant entitles its holder to subscribe
for one (1) ordinary share of the Company to be issued by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><I>Exercise price</I>: The exercise price of the OrbiMed Warrants (i.e., the price to be paid in cash
to subscribe for one new share in the Company when an OrbiMed Warrant is exercised) will be USD&nbsp;2.4134. The exercise price is subject
to potential customary downward adjustments in the case of certain dilutive actions of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify"><I>Subscription price</I>: The subscription price for the 881,906 OrbiMed Warrants to be issued for the
benefit of OrbiMed Royalty &amp; Credit Opportunities IV, LP will be USD&nbsp;1,744,485.56, and the subscription price for the 361,154
OrbiMed Warrants to be issued for the benefit of OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP will be USD&nbsp;714,394.11.
The subscription price shall be booked as issue premium (in accordance with what is stated in paragraph (d) below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify"><I>Term: </I>The OrbiMed Warrants will have a term of 5 years as from their issue date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify"><I>Exercisability:</I> The exercise of the OrbiMed Warrants will be subject to the terms and conditions
contained in the OrbiMed Warrants Terms and Conditions. The OrbiMed Warrants may be exercised as from their issuance and until the end
of their term.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(vi)</TD><TD STYLE="text-align: justify"><I>Transferability:</I> The OrbiMed Warrants and all rights thereunder are transferable, in whole or in
part, by the relevant holder in accordance with the OrbiMed Warrants Terms and Conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><U>Underlying shares</U>: Each OrbiMed Warrant will entitle its holder to subscribe for one new share
to be issued by the Company. The new shares to be issued upon exercise of the OrbiMed Warrants shall have the same rights and benefits
as, and rank <I>pari passu</I> in all respects including as to entitlements to dividends and other distributions, with the existing and
outstanding shares of the Company at the moment of their issuance and will be entitled to dividends and other distributions in respect
of which the relevant record date or due date falls on or after the date of their issuance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify"><U>Dis-application of the preferential subscription right for the benefit of OrbiMed</U>: The general
shareholders&rsquo; meeting resolves, in accordance with articles 7:191 and 7:193 of the Belgian Companies and Associations Code, to dis-apply,
in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required,
of the holders of subscription rights (share options) of the Company, for the benefit of each of OrbiMed Royalty &amp; Credit Opportunities
IV, LP and OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP, as explained in the report of the board of directors referred to
in item 5.(a) of the agenda.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify"><U>Conditional capital increase and issue of new shares</U>: The general shareholders&rsquo; meeting resolves,
subject to and in the case of the exercise of the OrbiMed Warrants, to increase the share capital of the Company and to issue the appropriate
number of new shares that may be issued upon exercise of the OrbiMed Warrants. Subject to, and in accordance with, the respective provisions
of the OrbiMed Warrants Terms and Conditions, upon exercise of the OrbiMed Warrants and the issuance of new shares, the aggregate amount
of the exercise price of the OrbiMed Warrants will be allocated to (as the case may be, following conversion into the Company&rsquo;s share
capital currency, on the basis of the relevant USD/EUR exchange ratio as shall be published by the European Central Bank, as provided
for in in section 4(b) of the OrbiMed Warrants Terms and Conditions) the share capital of the Company. To the extent that the amount of
the exercise price of the OrbiMed Warrants, per share to be issued upon exercise of the OrbiMed Warrants, exceeds the fractional value
of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise
price, per share to be issued upon exercise of the OrbiMed Warrants, equal to such fractional value shall be booked as share capital,
whereby the balance shall be booked as issue premium. Following the capital increase and issuance of new shares, each new and existing
share shall represent the same fraction of the share capital of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify"><U>Issue premium</U>: Any issue premium that will be booked in connection with the OrbiMed Warrants (whether
as subscription price, upon exercise of the OrbiMed Warrants, or otherwise) will be accounted for on a non-distributable account on the
liabilities side of the Company&rsquo;s balance sheet under its net equity, and the account on which the issue premium will be booked shall,
like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general
shareholders&rsquo; meeting passed in the manner required for an amendments to the Company&rsquo;s articles of association.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify"><U>Powers of attorney</U>: The board of directors is authorised to implement and execute the resolutions
adopted by the general shareholders&rsquo; meeting in connection with the OrbiMed Warrants, and to take all measures and carry out all formalities
that will be required pursuant to the OrbiMed Warrants Terms and Conditions, the Company&rsquo;s articles of association and all applicable
laws in order to issue or transfer the shares upon exercise of the OrbiMed Warrants. In addition, each director of the Company, Joe Sollee
and Ron Kalfus, each such person acting individually and with the possibility of sub-delegation and power of subrogation, shall have the
power, upon exercise of the OrbiMed Warrants, (i) to proceed with the recording of (A) the capital increase and the issue of new shares
resulting from such exercise, (B) the allocation as share capital and (if applicable) as issue premium, and (C) the amendment of the Company&rsquo;s
articles of association to reflect the new share capital and number of shares outstanding following the exercise of the OrbiMed Warrants
(ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Computershare, Nasdaq and/or bank documentation, the share
register and all other necessary documents in connection with the issuance and delivery of the shares to the beneficiary and the admission
to listing and trading of such shares, and (iii) to do whatever may be necessary or useful (including, but not limited to, the preparation
and execution of all documents and forms) for the admission of the shares issued upon exercise of the OrbiMed Warrants to trading on Nasdaq
(or any other market on which the Company&rsquo;s shares will then be traded).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Quorum:</B> As this extraordinary general shareholders&rsquo;
meeting constitutes the second extraordinary general shareholders&rsquo; meeting for the aforementioned agenda items, no quorum is required
for the deliberation and voting on the items referred to in the aforementioned agenda.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Voting and majority:</B> Subject to applicable
legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned
agenda of the extraordinary general shareholders&rsquo; meeting shall be passed if they are approved by a majority of 75% of the votes validly
cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights
have the right to participate to the extraordinary general shareholders&rsquo; meeting, but only with an advisory vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Participation
to the meeting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Introduction: </B>Holders of securities issued
by the Company who wish to participate to the extraordinary general shareholders&rsquo; meeting of the Company should take into account the
formalities and procedures described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the completion, on 18 December 2023, of
the Company&rsquo;s transition from a dual listing of the Company&rsquo;s former American Depositary Shares on Nasdaq and shares on Euronext
Brussels to a sole listing of its shares on Nasdaq, the Company&rsquo;s shares are comprised of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">shares that are reflected in the component of the Company&rsquo;s share register that is held in Belgium and
which is managed by Euroclear Belgium (the &ldquo;<B>Belgian Share Register</B>&rdquo; and, the shares reflected in the Belgian Share Register,
the &ldquo;<B>European Shares</B>&rdquo;), and that cannot be traded on Nasdaq until they have been repositioned into U.S. Shares (as defined
below); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">shares that are reflected directly or indirectly in the component of the Company&rsquo;s share register that
is held in the United States and which is managed by Computershare (the &ldquo;<B>U.S. Share Register</B>&rdquo; and, the shares reflected
in the U.S. Share Register, the &ldquo;<B>U.S. Shares</B>&rdquo;), and that can be traded on Nasdaq.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
further information and details regarding the transition to a single listing on Nasdaq and the repositioning process, please visit the
dedicated web page on the Company&rsquo;s website (see: </FONT>https://mdxhealth.com/proposed-transition-to-a-single-listing-on-nasdaq/<FONT STYLE="font-family: Times New Roman, Times, Serif">).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Registration date</B>: In accordance with article
32 of the Company&rsquo;s articles of association and article 7:134 of the Belgian Companies and Associations Code, the Company&rsquo;s board of directors
sets the registration date for the extraordinary general shareholders&rsquo; meeting on Monday, 17 June 2024, at midnight (12:00 a.m., Belgian
time) (the &ldquo;<B>Registration Date</B>&rdquo;). Only persons owning securities issued by the Company on Monday, 17 June 2024, at midnight
(12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the extraordinary general shareholders&rsquo;
meeting. Only shareholders are entitled to vote. The holders of subscription rights can participate to the extraordinary general shareholders&rsquo;
meeting, but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are
described under &ldquo;&mdash;Participation to the meeting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Participation to the meeting</B>: In order
to be able to participate to the extraordinary general meeting, a holder of securities issued by the Company must satisfy two conditions:
(a)&nbsp;be registered as holder of such securities on the Registration Date, and (b)&nbsp;notify the Company, as described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify"><I>Registration</I>: Firstly, the right for a holder of securities issued by the Company to participate
to and, as applicable, to vote at the extraordinary general shareholders&rsquo; meeting is only granted on the basis of the registration of
the securities concerned on the aforementioned Registration Date at midnight, as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Holders of registered European Shares and
registered subscription rights issued by the Company:</I> The holders of registered European Shares and subscription rights in registered
form issued by the Company may participate to the extraordinary general shareholders&rsquo; </FONT>meeting <FONT STYLE="font-family: Times New Roman, Times, Serif">only
for the registered European Shares and registered subscription rights that are reflected in their name in the Belgian Share Register and
relevant register of subscription rights, respectively, on the Registration Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Holders of dematerialised European Shares:
</I>The holders of dematerialised European Shares that want participate to the extraordinary general shareholders&rsquo; meeting must request
their certified account holder or the central securities depositary for the shares concerned to issue a certificate stating the number
of dematerialised shares registered in the name of the shareholder in its books on the Registration Date, and to send it to the Company
(</FONT>by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040
Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com) at the latest on the second business day prior to the
extraordinary general shareholders&rsquo; meeting, i.e., on or before Tuesday, 18 June 2024 at the latest (the &ldquo;<B>Notification Deadline</B>&rdquo;).
The Company shall determine the ownership of the relevant shares at the Registration Date solely on the basis of such certificates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify"><I>Holders of U.S. Shares, reflected directly in the U.S. Share Register (not through DTCC): </I><FONT STYLE="font-family: Times New Roman, Times, Serif">The
holders of U.S. Shares reflected directly in the U.S. Share Register (not through DTCC) may only be admitted to the extraordinary general
shareholders&rsquo; meeting if their ownership of U.S. Shares is reflected in the U.S. Share Register on the Registration Date. The </FONT>Company&rsquo;s
<FONT STYLE="font-family: Times New Roman, Times, Serif">U.S. transfer agent will no later than the Notification Deadline provide the
Company directly or indirectly with a shareholder list at the Registration Date that contains all of the registered holders of the Company&rsquo;s
U.S. Shares recorded in the U.S. Share Register directly (not through DTCC) on the Registration Date. The Company shall determine the
ownership of the relevant shares at the Registration Date solely on the basis of the aforementioned information. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify"><I>Holders of U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC):</I> The holders
of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE &amp; Co., the nominee holder of the U.S. Shares held for
the beneficial owners through the DTCC system, may only be admitted to the extraordinary general shareholders&rsquo; meeting if their ownership
of U.S. Shares is included in the information provided to the Company no later than the Notification Deadline through the broker, financial
institution or other intermediary of such shareholders. The Company shall determine the ownership of the relevant shares at the Registration
Date solely on the basis of the aforementioned information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify"><I>Notification</I>: Secondly, in accordance with article 32 of the Company&rsquo;s articles of association
and article 7:134 of the Belgian Companies and Associations Code, the Company&rsquo;s board of directors sets the deadline for holders of securities
issued by the Company to notify their participation to the extraordinary general shareholders&rsquo; meeting on the Notification Deadline. Therefore,
in order to participate to the extraordinary general shareholders&rsquo; meeting, holders of securities issued by the Company must notify the
Company whether they want to participate to the meeting, and the must do so prior to or at the latest on Tuesday, 18 June 2024. The holders
of securities who wish to make such notification can make use of the attendance form that can be obtained at the Company&rsquo;s registered
office and on the Company&rsquo;s website (http://www.mdxhealth.com). The notice must reach the Company, by mail at its registered office (MDxHealth
SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail
at agsm@mdxhealth.com, at the latest on the Notification Deadline. Depending on the type securities it holds, a holder of securities issued
by the Company must notify to the Company its participation to the extraordinary general shareholders&rsquo; meeting as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><I>Holders of registered European Shares <FONT STYLE="font-family: Times New Roman, Times, Serif">and
registered subscription rights issued by the Company</FONT></I>: Holders of registered European Shares <FONT STYLE="font-family: Times New Roman, Times, Serif">and
subscription rights in registered form issued by the Company</FONT> that wish to make such notification must make sure that the attendance
form is duly signed and completed and reaches the <FONT STYLE="font-family: Times New Roman, Times, Serif">Company</FONT> no later than
the Notification Deadline (pursuant to the instructions set out above).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><I>Holders of dematerialised European Shares</I>: Holders of dematerialised European Shares that wish
to make such notification must make sure that the attendance form is duly signed and completed and reaches the Company no later than the
Notification Deadline (pursuant to the instructions set out <FONT STYLE="font-family: Times New Roman, Times, Serif">above</FONT>). Furthermore,
the notification must include a certificate confirming the number of European Shares that have been registered in their name on the Registration
Date. The certificate can be obtained by the holders of the dematerialised European Shares with the <FONT STYLE="font-family: Times New Roman, Times, Serif">certified
account holder or the central securities depositary</FONT> for the European Shares concerned (see also under (ii) in paragraph (a) above).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify"><I>Holders of U.S. Shares, reflected directly in the U.S. Share Register (not through DTCC)</I>: Holders
of U.S. Shares reflected directly in the U.S. Share Register (not through DTCC) that wish <FONT STYLE="font-family: Times New Roman, Times, Serif">to</FONT>
make such notification must make sure that the attendance form included as part of their notice is duly completed and reaches the Company
no later than the Notification Deadline (pursuant to the instructions set out above).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify"><I>Holders of U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC)</I>: Holders
of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE &amp; Co., the nominee holder of the U.S. Shares held for
the beneficial owners through the DTCC system, that wish to make such notification must make sure that the attendance form is duly completed
and reaches the Company no later than the Notification Deadline (pursuant to the instructions <FONT STYLE="font-family: Times New Roman, Times, Serif">set</FONT>
out above). Furthermore, the notification must include a certificate from a <FONT STYLE="font-family: Times New Roman, Times, Serif">broker,
financial institution or other intermediary</FONT> indicating that such holder was the owner of such U.S. Shares on the Registration Date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company encourages shareholders to participate to the extraordinary general shareholders&rsquo; meeting through a signed proxy or the U.S. proxy
card (as further explained below </FONT>under &ldquo;&mdash;Representation by proxy&rdquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">)
that will be provided or is made available to them and in accordance with the accompanying instructions. </FONT>If a share<FONT STYLE="font-family: Times New Roman, Times, Serif">holder
</FONT>attends to the extraordinary general shareholders&rsquo; meeting in person, it may revoke its signed proxy or <FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
</FONT>proxy card until the Notification Deadline. Providing to the Company a signed proxy or U.S. proxy card to the Company shall also
qualify as a notification, provided that the signed proxy or <FONT STYLE="font-family: Times New Roman, Times, Serif">U.S. </FONT>proxy
card reaches the Company (by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue
d&rsquo;Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com) no later than the Notification Deadline.
For the shareholders referred to in (ii) and (iv) above, the signed proxy or <FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
</FONT>proxy card must also include the certificates referred to in (ii) and (iv) above respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Representation by proxy:</B> The holders of
securities can participate to the meeting and vote, as applicable, through a written proxy. Written proxies must contain specific voting
instructions for each proposed resolution. Proxy forms can be obtained on the Company&rsquo;s website (http://www.mdxhealth.com). The proxy
form must be signed in writing or electronically. Holders of U.S Shares who want to appoint a proxy are strongly encouraged to use the
U.S. proxy card that will be provided to them and according to the accompanying instructions<FONT STYLE="font-family: Times New Roman, Times, Serif">.
</FONT>Signed proxies and <FONT STYLE="font-family: Times New Roman, Times, Serif">U.S. </FONT>proxy cards must reach the Company by mail
at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium,
Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the Notification Deadline, i.e., on or before <FONT STYLE="font-family: Times New Roman, Times, Serif">Tuesday,
18 June 2024</FONT> at the latest. Holders of securities who wish to be represented by proxy must, in any case comply with the formalities
to participate to the meeting, as explained under &ldquo;&mdash;Participation to the meeting&rdquo;. For the shareholders referred to in
(ii) and (iv) of paragraph (b) of &ldquo;&mdash;Participation to the meeting&rdquo;, the signed proxy or <FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
</FONT>proxy card must also include the certificates referred to in (ii) and (iv), respectively, of paragraph (b) of &ldquo;&mdash;Participation
to the meeting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Access to the meeting room</B>: The natural
persons who attend the extraordinary general shareholders&rsquo; meeting in their capacity as holder of securities, holder of proxies or representative
of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what
is shared above under &ldquo;&mdash;General information&rdquo;). In addition, the representatives of legal entities must hand over the documents
establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start
of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recommendation to use e-mail:</B> The Company
recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders&rsquo; meeting.
The Company&rsquo;s e-mail address for such communication is: agsm@mdxhealth.com. The Company also points at that, in addition to be physically
available at the Company&rsquo;s registered office and distributed by mail, all forms and other documentation in relation to the general shareholders&rsquo;
meeting will be available on the Company&rsquo;s website (http://www.mdxhealth.com). See also &ldquo;&mdash;Available documentation&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Unofficial English translation
&ndash; For informational purposes only</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Data
Protection</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Th</FONT>e Company
is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and
proxy holders in the context of general shareholders&rsquo; meeting. The processing of such data will be carried out for the purposes of the
organisation and conduct of the relevant general shareholders&rsquo; meeting, including the convening notices, registrations, participation
and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base
of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued
by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or
services to the Company in connection with the foregoing. The processing of such data will be carried out, <I>mutatis mutandis</I>, in
accordance with the Company&rsquo;s Privacy Policy, available on the Company&rsquo;s website (https://mdxhealth.com/privacy-policy). The Company draws
the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data
subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in
the aforementioned Privacy Policy. All this does not affect the rules that apply in connection with the registration and participation
to the general shareholders&rsquo; meeting. To exercise rights as a data subject and for all other information regarding the processing of personal
data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@mdxhealth.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>available
documentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following documentation is available on the
Company&rsquo;s website (http://www.mdxhealth.com): the notice convening the extraordinary general shareholders&rsquo; meeting, the documents to be
submitted to the extraordinary general shareholders&rsquo; meeting as referred to in the agenda of the meeting, the attendance form, and the
proxy form. Prior to the extraordinary general shareholders&rsquo; meeting, holders of securities of the Company can also obtain at the registered
office of the Company (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium), free of cost,
a copy of this documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please address any correspondence on this matter
to MDxHealth SA, Mr. Ron Kalfus CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium. The facsimile
number is +32&nbsp;(0)4&nbsp;259 78 75 and the e-mail address is agsm@mdxhealth.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of the board of directors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">This document
is not an offer to sell or a solicitation of an offer to buy shares or other securities of mdxhealth sa. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">11</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>ea020737001ex99-2_mdxhealth.htm
<DESCRIPTION>EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING NOTICE LETTER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-2_001.jpg" ALT="" STYLE="height: 31px; width: 200px"></P>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 85%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MDxHealth SA</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAP Business Center</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rue d'Abhooz, 31</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B-4040 Herstal - Belgium</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T. +32 (0) 4 257 70 21</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F. +32 (0) 4 259 78 75</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>June 3, 2024</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E. <U>info@mdxhealth.com</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">www.mdxhealth.com</FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Shareholder,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-align: justify; text-indent: -31.5pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B><U>Re</U>:</B></TD><TD STYLE="text-align: justify"><B>Extraordinary general shareholders' meeting of MDxHealth SA to be held on June 20, 2024 </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of the Board of Directors of MDxHealth
SA (the &ldquo;Company&rdquo;), you are cordially invited to attend the 2024 extraordinary general shareholders&rsquo; meeting (the &quot;<B>Extraordinary
Meeting</B>&rdquo;) to be held in-person on Thursday, June 20, 2024, at 3:00 p.m. (Belgian time) at the offices of the notary public Stijn
Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The agenda, proposed resolutions and the other
documents for the Extraordinary Meeting are available in French and English on the Company's website (see: https://www.mdxhealth.com/shareholder-information/).
We encourage you to read these materials carefully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Whether or not you plan to attend the meeting,
your vote is important, and we encourage you to vote promptly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a description of the formalities to be fulfilled
by holders of securities of the Company to participate and vote at the Extraordinary Meeting, please see notice convening the meeting,
which can be found on the Company's website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also vote your shares through one of the
methods described in the accompanying proxy card.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael K. McGarrity<BR>
CEO &amp; Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">TVA
BE 0479 292 440 </FONT><FONT STYLE="font-family: Wingdings">w</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">RCB 212
29 </FONT><FONT STYLE="font-family: Wingdings">w</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">ING Bank 736-0304341-19</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF MDXHEALTH SA<BR>
EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>JUNE 20, 2024 3:00 P.M. (Belgian Time)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">At the offices of the notary public Stijn Raes, at Kortrijksesteenweg
1147, 9051 Ghent, Belgium</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Shareholders of MDxHealth SA:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2024 extraordinary general shareholders&rsquo; meeting (the &quot;<B>Extraordinary
Meeting</B>&rdquo;) to be held in-person on Thursday, June 20, 2024, at 3:00 p.m. Central European Time at the offices of the notary public
Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The purpose of the meeting is to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: justify"><U>Extraordinary Meeting</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"> &#9679;</TD><TD STYLE="text-align: justify">Report on and approve the 2024 Share Option Plan and 2,000,000 2024 Share Options</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"> &#9679;</TD><TD STYLE="text-align: justify">Report on and approve 1,000,000 Exact Sciences Warrants</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"> &#9679;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Report on and approve 1,243,060 OrbiMed Warrants</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.7pt; text-align: justify; text-indent: -17.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The detailed agenda, proposed resolutions and
the other documents for the Extraordinary Meeting are available in French and English on the Company's website (see: https://www.mdxhealth.com/shareholder-information/).
We encourage you to read these materials carefully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU PLAN
TO ATTEND THE MEETING, PLEASE VOTE YOUR SHARES IN ACCORDANCE WITH THE INSTRUCTIONS SET OUT ON THE ACCOMPANYING PROXY CARD. PROXY CARDS
SHOULD BE DATED, SIGNED AND RETURNED <B><U>FOR RECEIPT BY OR BEFORE JUNE 17, 2024</U></B>. YOUR PROMPT COOPERATION IS GREATLY APPRECIATED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt">On behalf of the
board of directors</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Joseph Sollee</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">General Counsel
&amp; Secretary of the Board of Directors</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TVA BE 0479 292 440 &#9679; RCB 212 29 &#9679; ING Bank 310-1801580-85</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>ea020737001ex99-3_mdxhealth.htm
<DESCRIPTION>ATTENDANCE FORM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MDxHealth SA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Limited Liability Company<BR>
(<I>soci&eacute;t&eacute; anonyme</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><BR>
CAP Business Center</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Zone Industrielle des Hauts-Sarts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Rue d&rsquo;Abhooz 31<BR>
4040 Herstal, Belgium<BR>
VAT BE 0479.292.440 (RLP Li&egrave;ge, division Li&egrave;ge)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 1pt 5.4pt; width: 100%; border: Black 1pt solid">

    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ATTENDANCE FORM FOR SECURITY HOLDERS</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Extraordinary
    General Meeting</B></FONT><B><BR>
    </B>to be held on Thursday, 20 June 2024, at 3:00 p.m. (Belgian time)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 100%; border: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This attendance form should be used by holders
    of securities of MDxHealth SA (the &ldquo;<B>Company</B>&rdquo;) who want to attend the extraordinary general shareholders&rsquo; meeting in person.
    More information regarding the requirements for, and the modalities of, participation in the meeting can be found in the convening notice
    of the extraordinary general shareholders&rsquo; meeting.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The signed and completed form must reach the Company
    at the latest on the second business day prior to the extraordinary general shareholders&rsquo; meeting, <I>i</I>.e., <B><U>on or before Tuesday,
    18 June&nbsp;2024</U></B> at the latest, by mail to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">MDxHealth SA<BR>
    Attention Mr. Ron Kalfus<BR>
    Company Secretary</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CAP Business Center</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Zone Industrielle des Hauts-Sarts<BR>
    Rue d&rsquo;Abhooz, 31<BR>
    4040 Herstal,<BR>
    Belgium</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">or by e-mail to:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">agsm@mdxhealth.com</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The use of e-mail
    is strongly encouraged. </FONT></P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">The Company&rsquo;s
    shares are comprised of: (a) shares that are reflected in the component of the Company&rsquo;s share register that is held in Belgium and which
    is managed by Euroclear Belgium (the &ldquo;</FONT>Belgian Share Register<FONT STYLE="font-weight: normal">&rdquo; and, the shares reflected
    in the Belgian Share Register, the &ldquo;</FONT>European Shares<FONT STYLE="font-weight: normal">&rdquo;), and that cannot be traded on
    Nasdaq until they have been repositioned into U.S. Shares (as defined below), and (b) shares that are reflected directly or indirectly
    in the component of the Company&rsquo;s share register that is held in the United States and which is managed by Computershare (the &ldquo;</FONT>U.S.
    Share Register<FONT STYLE="font-weight: normal">&rdquo; and, the shares reflected in the U.S. Share Register, the &ldquo;</FONT>U.S. Shares<FONT STYLE="font-weight: normal">&rdquo;),
    and that can be traded on Nasdaq.</FONT></P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>
    <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Holders
    of dematerialised European Shares must attach to the present form a certificate issued by the certified account holder or the central
    securities depositary for the shares concerned, confirming the number of dematerialised European Shares that have been registered in their
    name on the registration date (i.e., Monday, 17 June&nbsp;2024, at midnight (12:00 a.m., Belgian time)) (the &ldquo;</FONT>Registration
    Date<FONT STYLE="font-weight: normal">&rdquo;), with which they want to participate to the extraordinary general shareholders&rsquo; meeting.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-weight: normal">Holders of U.S.
    Shares reflected indirectly in the U.S. Share Register, through CEDE &amp; Co., the nominee holder of the U.S. Shares held for the beneficial
    owners through the DTCC system, must attach to the present form a certificate from a broker, financial institution or other intermediary
    confirming their ownership of U.S. Shares on the Registration Date, with which they want to participate to the extraordinary general shareholders&rsquo;
    meeting.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD COLSPAN="1" STYLE="font-size: 10pt; padding-left: 5.4pt; border-top: Black 1pt solid; font-weight: bold"><FONT STYLE="font-size: 10pt">Extraordinary General Shareholders&rsquo; Meeting of MDxHealth
    SA - Attendance form for security holders</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The undersigned,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>First Name:</B></P></TD>
    <TD STYLE="width: 58%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family Name:</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address:</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate name:</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate form:</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registered office:</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Represented by (first name, family name and capacity):</B></FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">owner of the following number of securities issued
by MDxHealth SA, with registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding: 2pt 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.<I><SUP>(1)</SUP></I>
    registered European Shares</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.&hellip;&hellip;&hellip;<I><SUP>(1)</SUP></I>
    dematerialised European Shares</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 225pt; text-indent: -153pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;..<I><SUP>(1)
    </SUP></I>U.S. Shares reflected directly in the U.S. Share Register (not through DTCC)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 225pt; text-indent: -153pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 225pt; text-indent: -153pt">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;..<I><SUP>(1)</SUP></I>
    U.S. Shares reflected indirectly in the U.S. Share Register (through DTCC)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 225pt; text-indent: -153pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -2.25in">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.&hellip;&hellip;.&hellip;<I><SUP>(1)</SUP></I>
    subscription rights <I><SUP>(2)</SUP></I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-indent: -2.25in">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 2pt 5.4pt; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes:</I></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(1)</I></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Number of relevant securities to be completed, when applicable.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(2)</I></FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders&rsquo; meeting, but only with an advisory vote.</I></FONT></TD></TR>
  <TR>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Hereby notifies his/her/its intent to attend the
extraordinary general shareholders&rsquo; meeting of MDxhealth&nbsp;SA to be held on Thursday, 20 June 2024, at 3:00 p.m. (Belgian time) at
the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place indicated at that
place at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned agrees that the English translation
of the present attendance form is a free translation and for information purposes only, and that the French version shall prevail over
the English translation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="padding-left: 5.4pt; border-top: Black 1pt solid; font-weight: bold"><FONT STYLE="font-size: 10pt">Extraordinary General Shareholders&rsquo; Meeting of MDxHealth
    SA - Attendance form for security holders</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby confirms that the Company
can send all confirmations and information required for participation in the extraordinary general shareholders&rsquo; meeting to the
following e-mail address of the undersigned:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -1pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(E-mail address of security holder)</I></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">Done at &hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.,
on &hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">Signature&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="1" STYLE="padding-left: 5.4pt; border-top: Black 1pt solid; font-weight: bold"><FONT STYLE="font-size: 10pt">Extraordinary General Shareholders&rsquo; Meeting of MDxHealth
    SA - Attendance form for security holders</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>5
<FILENAME>ea020737001ex99-4_mdxhealth.htm
<DESCRIPTION>PROXY FORM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 99.4</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E6E6E6">

    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; vertical-align: top; text-align: justify; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Assembl&Eacute;e
g&Eacute;n&Eacute;rale extraordinaire des Actionnaires</B></FONT></P>

<P STYLE="text-align: center; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>20
<FONT STYLE="text-transform: uppercase">juin</FONT> 2024</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; vertical-align: top; text-align: center; width: 50%"><B>EXTRA<FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ordinary
    general shareholders&rsquo; meeting<BR> 20 June 2024</FONT></B></TD></TR>
</TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #E6E6E6">
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; vertical-align: top; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Procuration</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; vertical-align: top; text-align: center; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Proxy</B></FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cette procuration doit &ecirc;tre utilis&eacute;e
par les titulaires de titres de MDxHealth&nbsp;SA (la &ldquo;<B>Soci&eacute;t&eacute;</B>&rdquo;) qui d&eacute;sirent &ecirc;tre repr&eacute;sent&eacute;s
par un mandataire sp&eacute;cial &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires de la Soci&eacute;t&eacute;
&agrave; tenir le jeudi 20 juin 2024 &agrave; 15h00 (heure belge). Nonobstant ce qui pr&eacute;c&egrave;de, les titulaires d&rsquo;Actions Am&eacute;ricaines
(telles que d&eacute;finies ci-dessous) qui souhaitent d&eacute;signer un mandataire sont vivement encourag&eacute;s &agrave; utiliser
la carte de procuration am&eacute;ricaine (<I>U.S. proxy card</I>) qui leur a &eacute;t&eacute; fournie et &agrave; suivre les instructions
qui l&rsquo;accompagnent.</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy should be used by holders of securities
of MDxHealth SA (the &ldquo;<B>Company</B>&rdquo;) who want to be represented by a proxy holder at the extraordinary general shareholders&rsquo;
meeting of the Company to be held on Thursday, 20 June 2024, at 3:00 p.m. (Belgian time). Notwithstanding the above, holders of U.S. Shares
(as defined below) who want to appoint a proxy are strongly encouraged to use the U.S. proxy card provided to them and according to the
accompanying instructions.</P>
<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Les actions de la Soci&eacute;t&eacute; se composent: (a) d&rsquo;actions inscrites dans la composante du registre des actions de la Soci&eacute;t&eacute; qui est tenue en Belgique et qui est
maintenue par Euroclear Belgium (le &ldquo;<B>Registre Belge des Actions</B>&rdquo; et, les actions refl&eacute;t&eacute;es dans le Registre
Belge des Actions, les &ldquo;<B>Actions Europ&eacute;ennes</B>&rdquo;), et qui ne peuvent pas &ecirc;tre n&eacute;goci&eacute;es sur le
Nasdaq tant qu&rsquo;elles n&rsquo;ont pas &eacute;t&eacute; repositionn&eacute;es en Actions Am&eacute;ricaines (telles que d&eacute;finies ci-dessous),
et (b) d&rsquo;actions inscrites directement ou indirectement dans la composante du registre des actions de la Soci&eacute;t&eacute; tenue aux
&Eacute;tats-Unis et qui est maintenue par Computershare (le &ldquo;<B>Registre Am&eacute;ricain des Actions</B>&rdquo; et, les actions
figurant dans le Registre Am&eacute;ricain des Actions, les &ldquo;<B>Actions Am&eacute;ricaines</B>&rdquo;), et qui peuvent &ecirc;tre
n&eacute;goci&eacute;es sur le Nasdaq.</P>

</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s shares are comprised of: (a) shares
that are reflected in the component of the Company&rsquo;s share register that is held in Belgium and which is managed by Euroclear Belgium
(the &ldquo;<B>Belgian Share Register</B>&rdquo; and, the shares reflected in the Belgian Share Register, the &ldquo;<B>European Shares</B>&rdquo;),
and that cannot be traded on Nasdaq until they have been repositioned into U.S. Shares (as defined below), and (b) shares that are reflected
directly or indirectly in the component of the Company&rsquo;s share register that is held in the United States and which is managed by Computershare
(the &ldquo;<B>U.S. Share Register</B>&rdquo; and, the shares reflected in the U.S. Share Register, the &ldquo;<B>U.S. Shares</B>&rdquo;),
and that can be traded on Nasdaq.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cette procuration ne constitue pas une sollicitation
publique de procuration au sens des article 7:145 du Code des soci&eacute;t&eacute;s et des associations.</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This proxy does not constitute a proxy solicitation
in the sense of article 7:145 of the Belgian Companies and Associations Code.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">La procuration doit &ecirc;tre sign&eacute;e de
fa&ccedil;on &eacute;crite ou &eacute;lectroniquement.</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proxy must be signed in writing or electronically.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">La procuration sign&eacute;e et
                                                                                                                                 compl&eacute;t&eacute;e doit parvenir &agrave; la Soci&eacute;t&eacute; au plus tard le deuxi&egrave;me jour ouvrable qui
                                                                                                                                 pr&eacute;c&egrave;de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires, soit <B><U>le, ou avant le, mardi
                                                                                                                                 18 juin </U>2024 </B>(la &ldquo;<B>Date limite de Notification</B>&rdquo;) au plus tard. Jusqu&rsquo;&agrave; cette date, les procurations
                                                                                                                                 peuvent &ecirc;tre envoy&eacute;es &agrave; l&rsquo;adresse suivante:</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The signed and completed proxy must reach the
Company at the latest on the second business day prior to the extraordinary general shareholders&rsquo; meeting, i.e. <B><U>on or before Tuesday,
18 June 2024</U></B> (the &ldquo;<B>Notification Deadline</B>&rdquo;) at the latest. Until the Notification Deadline, proxies can be sent
to the following address:</P>
<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 7pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">MDxHealth
    SA<BR> A l&rsquo;attention de M. Ron Kalfus<BR> Secr&eacute;taire de la Soci&eacute;t&eacute;<BR> CAP Business Center <BR>
    Zone Industrielle des Hauts-Sarts<BR>
    Rue d&rsquo;Abhooz 31,<BR> 4040 Herstal <BR>
Belgique </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 4pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">MDxHealth
    SA<BR> Attention Mr. Ron Kalfus<BR> Company Secretary <BR>
    CAP Business Center <BR>
    Zone Industrielle des Hauts-Sarts<BR> Rue d&rsquo;Abhooz, 31<BR> 4040 Herstal,<BR> Belgium</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">ou
    par courrier &eacute;lectronique &agrave;:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">or
    by e-mail to:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">agsm@mdxhealth.com</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agsm@mdxhealth.com</FONT></TD></TR>
  <TR STYLE="font: 7pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 7pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 7pt Times New Roman, Times, Serif; padding-left: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Les titulaires de titres de la Soci&eacute;t&eacute;
qui d&eacute;sirent &ecirc;tre repr&eacute;sent&eacute;s par procuration doivent aussi s&rsquo;enregistrer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale
extraordinaire des actionnaires, tel que d&eacute;crit dans l&rsquo;invitation &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire
des actionnaires. Les titulaires d&rsquo;Actions Europ&eacute;ennes d&eacute;mat&eacute;rialis&eacute;s doivent joindre &agrave; ce formulaire
un certificat d&eacute;livr&eacute; par le teneur de compte agr&eacute;&eacute; ou le d&eacute;positaire central de titres pour les actions
concern&eacute;es, confirmant le nombre d&rsquo;Actions Europ&eacute;ennes d&eacute;mat&eacute;rialis&eacute;es ayant &eacute;t&eacute; enregistr&eacute;s
&agrave; leur nom &agrave; la date d&rsquo;enregistrement (soit le lundi 17 juin 2024, &agrave; minuit (00h00, heure belge)) (la &ldquo;<B>Date
d&rsquo;Enregistrement</B>&rdquo;) et avec lesquelles ils veulent participer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire
des actionnaires. Les titulaires d&rsquo;Actions Am&eacute;ricaines inscrites indirectement dans le Registre Am&eacute;ricain des Actions, par
l&rsquo;interm&eacute;diaire de CEDE &amp; Co, le d&eacute;tenteur d&eacute;sign&eacute; des Actions Am&eacute;ricaines d&eacute;tenues pour
les b&eacute;n&eacute;ficiaires effectifs via le syst&egrave;me DTCC, doivent joindre au pr&eacute;sent formulaire un certificat d&rsquo;un
courtier, d&rsquo;une institution financi&egrave;re ou d&rsquo;un autre interm&eacute;diaire confirmant leur propri&eacute;t&eacute; des Actions Am&eacute;ricaines
&agrave; la Date d&rsquo;Enregistrement, avec lesquelles ils souhaitent participer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire
des actionnaires.</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of securities of the Company who wish
to be represented by proxy must also register for the extraordinary general shareholders&rsquo; meeting, as described in the notice convening
the extraordinary general shareholders&rsquo; meeting. Holders of dematerialised European Shares must attach to the present form a certificate
issued by the certified account holder or the central securities depositary for the shares concerned, confirming the number of dematerialised
European Shares that have been registered in their name on the registration date (i.e., Monday, 17 June 2024, at midnight (12:00 a.m.,
Belgian time)) (the &ldquo;<B>Registration Date</B>&rdquo;), with which they want to participate to the extraordinary general shareholders&rsquo;
meeting. Holders of U.S. Shares reflected indirectly in the U.S. Share Register, through CEDE &amp; Co., the nominee holder of the U.S.
Shares held for the beneficial owners through the DTCC system, must attach to the present form a certificate from a broker, financial
institution or other intermediary confirming their ownership of U.S. Shares on the Registration Date, with which they want to participate
to the extraordinary general shareholders&rsquo; meeting.</P></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">La Soci&eacute;t&eacute; recommande d&rsquo;utiliser
le courrier &eacute;lectronique pour toute communication avec la Soci&eacute;t&eacute; concernant l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale
des actionnaires.</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The Company recommends to use e-mail for all communication with the
Company regarding the general shareholders&rsquo; meeting.</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Le/La soussign&eacute;(e),</P></TD>
    <TD STYLE="padding-left: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 50%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">The undersigned,</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pr&eacute;nom
    / First name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nom
    de famille / Family name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adresse
    / Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ou
    / or</FONT></TD>
    <TD STYLE="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D&eacute;nomination
    / Corporate name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forme
    juridique / Corporate form:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Si&egrave;ge
    / Registered office:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repr&eacute;sent&eacute;
    par (pr&eacute;nom, nom de famille et qualit&eacute;) /</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0.25in"> Represented by (first name, family name and capacity):</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; width: 50%; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">titulaire du (des) nombre(s) suivant(s) de titres &eacute;mis par MDxHealth
SA, ayant son si&egrave;ge au CAP Business Center, Zone Industrielle des Hauts-Sarts, Rue d&rsquo;Abhooz 31, 4040 Herstal, Belgique,</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; width: 50%; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">owner of the following number of securities issued by MDxHealth SA,
with its registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d&rsquo;Abhooz 31, 4040 Herstal, Belgium,</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0in; width: 70%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nombre d&rsquo;Actions Europ&eacute;ennes nominatives
/ Number of registered European Shares:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nombre d&rsquo;Actions Europ&eacute;ennes d&eacute;mat&eacute;rialis&eacute;es
/ Number of dematerialised European Shares:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nombre d&rsquo;Actions Am&eacute;ricaines, inscrites
directement dans le Registre Am&eacute;ricain des Actions (pas par l&rsquo;interm&eacute;diaire de DTCC) / Number of U.S. Shares reflected directly
in the U.S. Share Register (not through DTCC):</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Nombre d&rsquo;Actions Am&eacute;ricaines, inscrites indirectement dans le
Registre Am&eacute;ricain des Actions (par l&rsquo;interm&eacute;diaire de DTCC) / Number of U.S. Shares reflected indirectly in the U.S. Share
Register (through DTCC):</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding-left: 0in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nombre de droits de souscription / Number of subscription
rights:<SUP>1</SUP></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify; width: 50%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">constitue pour mandataire sp&eacute;cial, avec pouvoir de substitution:</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">appoints as his/her/its proxy holder, with power of substitution:</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
M./Mme / Mr./Ms.__________________________________________________________<SUP>2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
Pr&eacute;sident du conseil d&rsquo;administration / Chair of the board of
directors<SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; width: 50%; padding-right: 4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify; text-indent: -2.75pt"><I><SUP>1 </SUP>Conform&eacute;ment
&agrave; l&rsquo;article 7:135 du Code des soci&eacute;t&eacute;s et des associations, les titulaires de droits de souscription ont le droit
de participer &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires mais seulement avec voix consultative.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify; text-indent: -2.75pt"><I>&nbsp;</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.75pt; text-align: justify; text-indent: -2.75pt"><I><SUP>2 </SUP>Veuillez
    compl&eacute;ter tel qu&rsquo;appropri&eacute;. Une absence d&rsquo;instruction sera interpr&eacute;t&eacute;e comme une nomination du pr&eacute;sident
    du conseil d&rsquo;administration en tant que mandataire.</I></P></TD>
    <TD STYLE="width: 50%; padding-left: 4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><SUP>1 </SUP>Pursuant to article 7:135 of the
    Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders&rsquo; meeting, but only
    with an advisory vote.</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><SUP>2 </SUP>Please complete as appropriate.
    An absence of instruction shall be tantamount to an appointment of the chair of the board of directors as proxy holder.</I></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I><SUP>3 </SUP>Le pr&eacute;sident du conseil d'administration de la Soci&eacute;t&eacute;
<I>a le pouvoir de nommer un autre administrateur, un employ&eacute; ou rempla&ccedil;ant d&eacute;sign&eacute; de la Soci&eacute;t&eacute;
comme suppl&eacute;ant en vertu d'une sous-d&eacute;l&eacute;gation si le pr&eacute;sident est emp&ecirc;ch&eacute; d'assister &agrave;
l'assembl&eacute;e g&eacute;n&eacute;rale des actionnaires. Le pr&eacute;sident ou son suppl&eacute;ant ne vote qu'en ex&eacute;cution
de la procuration, conform&eacute;ment aux instructions de vote sp&eacute;cifiques figurant dans la procuration. Voir &eacute;galement
la note 2 ci-dessous.</I></I></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I><SUP>3 </SUP>The chair of the board of directors of the Company has the power to appoint another director, employee or substitute of the Company as a substitute pursuant to a sub delegation if the chair is hindered to attend the general shareholders&rsquo; meeting. The chair or his substitute may only vote in execution of the proxy, in accordance with the specific voting instructions included in the proxy. See also note 2 below.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt">lequel accepte ainsi d&rsquo;&ecirc;tre nomm&eacute;, et &agrave; qui le/la soussign&eacute;(e) donne les pouvoirs et instructions de vote sp&eacute;cifiques suivants:<SUP>4</SUP></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt">who agrees to be so appointed, and to whom the undersigned gives the following powers and specific voting instructions:<SUP>4</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I><SUP>4 </SUP>Veuillez indiquer l&rsquo;instruction
de vote dans les cases appropri&eacute;es pour les points &agrave; l&rsquo;ordre du jour. En l&rsquo;absence d&rsquo;une instruction de vote pour un point
de l&rsquo;ordre du jour, ou dans le cas o&ugrave;, pour quelque raison que ce soit, il y aurait un manque de clart&eacute; concernant les
instructions de vote, le mandataire sera pr&eacute;sum&eacute; avoir vot&eacute; &ldquo;en faveur&rdquo; des r&eacute;solutions propos&eacute;es
soutenues par le conseil d&rsquo;administration et cela sera consid&eacute;r&eacute; comme une instruction de vote sp&eacute;cifique au sens
de l&rsquo;article 7:143 &sect;4 2&deg; du Code des soci&eacute;t&eacute;s et des associations.</I></P></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><I><SUP>4 </SUP>Please indicate the voting instructions in the appropriate boxes of the agenda items. In the absence of voting instructions for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions, the proxy holder will be presumed to have voted &ldquo;in favour&rdquo; of the proposed resolutions supported by the board of directors and that this will be deemed to be a specific voting instruction in the sense of article 7:143 &sect;4 2&deg; of the Belgian Companies and Associations Code.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
    <TD STYLE="padding-left: 4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>I. </B>De
    repr&eacute;senter le/la soussign&eacute;(e) &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire des actionnaires
    &agrave; tenir le jeudi 20 juin 2024 &agrave; 15h00 (heure belge), dans les bureaux de Ma&icirc;tre Stijn Raes, notaire, &agrave;
    Kortrijksesteenweg 1147, 9051 Gand, Belgique, ou &agrave; tout autre endroit qui sera indiqu&eacute; &agrave; cette
    occasion.</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify; text-indent: 1pt"><FONT STYLE="font-size: 10pt"><B>I. </B>To represent the undersigned at the extraordinary general meeting of
shareholders to be held on Thursday, 20 June 2024 at 3:00 p.m. (Belgian time), at the offices of the notary public Stijn Raes, at Kortrijksesteenweg
1147, 9051 Ghent, Belgium, or at such place as will be indicated at that place at that time.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #D9D9D9">
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 4pt; padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ORDRE
                                            DU JOUR</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B STYLE="text-decoration: none">ASSEMBLEE GENERALE EXTRAORDINAIRE</B></FONT></P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; padding-right: 4pt; padding-left: 4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>agenda</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>extraordinary
    general meeting</B></FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify; width: 50%">1.
    &nbsp;&nbsp;&nbsp;<U>Communication des rapports - Plan d&rsquo;Option sur Action de 2024</U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify; width: 50%">1. &nbsp; <U>Submission
    of reports - 2024 Share Option Plan</U>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify">&nbsp; &nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; padding-right: 4pt; text-align: justify">Communication et discussion sur:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: justify">&nbsp;&nbsp;&nbsp;Submission of and discussion on:</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">a)&nbsp;&nbsp;&nbsp;&nbsp;le rapport du conseil d&rsquo;administration de la Soci&eacute;t&eacute;, pr&eacute;par&eacute;
conform&eacute;ment aux articles 7:180 et 7:191 du Code des soci&eacute;t&eacute;s et associations relatif &agrave; la proposition d&rsquo;&eacute;mettre
2.000.000 nouveaux droits de souscription de la Soci&eacute;t&eacute; (les &ldquo;<B>2024 Share Options</B>&rdquo;), en vertu d&rsquo;un plan
d&rsquo;option sur action d&eacute;nomm&eacute; &ldquo;<B>le Plan d&rsquo;Option sur Action de 2024</B>&rdquo;, et de supprimer, dans l&rsquo;int&eacute;r&ecirc;t
de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants de la Soci&eacute;t&eacute; et, pour autant
que de besoin, des d&eacute;tenteurs de droits de souscription en circulation (share options) de la Soci&eacute;t&eacute;, en faveur des
membres du personnel de la Soci&eacute;t&eacute; et de ses filiales de temps &agrave; autre, au sens de l&rsquo;article 1:27 du Code des soci&eacute;t&eacute;s
et des associations (les &ldquo;<B>Participants S&eacute;lectionn&eacute;s</B>&rdquo;); et</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">a)&nbsp;&nbsp;&nbsp;&nbsp;the report of the board of directors of the Company, prepared in accordance with
articles 7:180 and 7:191 of the Belgian Companies and Associations Code, in relation to the proposal to issue 2,000,000 new subscription
rights for shares of the Company (the &ldquo;<B>2024 Share Options</B>&rdquo;), pursuant to a share option plan named &ldquo;<B>the 2024
Share Option Plan</B>&rdquo;, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders
of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, for the benefit
of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian
Companies and Associations Code (the &ldquo;<B>Selected Participant</B>&rdquo;); and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">b)&nbsp;&nbsp;&nbsp;&nbsp;le rapport du commissaire de la Soci&eacute;t&eacute;, pr&eacute;par&eacute; conform&eacute;ment aux articles 7:180 et 7:191 du Code des soci&eacute;t&eacute;s et des associations, concernant la proposition d&rsquo;&eacute;mettre 2.000.000 2024 Share Options et de supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription en circulation (share options) de la Soci&eacute;t&eacute;, en faveur des Participant S&eacute;lectionn&eacute;s.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">b)&nbsp;&nbsp;&nbsp;&nbsp;the report of the statutory auditor of the Company in accordance with articles
7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 2,000,000 2024 Share Options, and
to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar
as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, to the benefit of the Selected
Participants.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">2. &nbsp;&nbsp;&nbsp;
    <U>Proposition d&rsquo;&eacute;mettre 2.000.000 2024 Share Options</U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify">2. &nbsp; <U>Proposal to issue 2,000,000
    2024 Share Options</U></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&#9658;&nbsp;&nbsp;
    <B><I><U>Proposition de r&eacute;solution:</U></I></B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 4pt; text-align: justify">&#9658; <B><I><U>Proposed resolution:</U></I></B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; padding-right: 4pt; text-align: justify">L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires d&eacute;cide d&rsquo;approuver l&rsquo;&eacute;mission de 2.000.000
2024 Share Options, en vertu d&rsquo;un plan d&rsquo;option sur action d&eacute;nomm&eacute; &ldquo;le Plan d&rsquo;Option sur Action de 2024&rdquo;, et de
supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants de
la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription en circulation (share options)
de la Soci&eacute;t&eacute;, en faveur des Participants S&eacute;lectionn&eacute;s. En cons&eacute;quence, le conseil d&rsquo;administration
d&eacute;cide de ce qui suit:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; padding-right: 4pt; text-align: justify">The general shareholders&rsquo; meeting resolves to approve the issuance
of 2,000,000 2024 Share Options, pursuant to a share option plan named the &ldquo;2024 Share Option Plan&rdquo;, and to dis-apply, in the
interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of
the holders of outstanding subscription rights (share options) of the Company, for the benefit of Selected Participant. In view thereof,
the general shareholders&rsquo; meeting resolves as follows:</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;<U>Termes et conditions
des 2024 Share Options:</U> Les termes et conditions des 2024 Share Options (inclus, mais sans s&rsquo;y limiter, le prix d&rsquo;exercice des 2024
Share Options) seront tels que figurant dans l&rsquo;annexe au rapport du conseil d&rsquo;administration vis&eacute; au point 1.(a) de l&rsquo;ordre du
jour (aux fins de la pr&eacute;sente r&eacute;solution, le &ldquo;Plan&rdquo;), dont une copie restera jointe proc&egrave;s-verbal constatant
la pr&eacute;sente r&eacute;solution. Les 2024 Share Options ont une dur&eacute;e de 10 ans &agrave; partir de leur date d&rsquo;&eacute;mission.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;<U>Terms and conditions
of the 2024 Share Options:</U> The terms and conditions of the 2024 Share Options (including, but not limited to, the exercise price of
the 2024 Share Options) shall be as set out in the annex to the report of the board of directors referred to in item 1.(a) of the agenda
(for the purpose of this resolution, the &ldquo;Plan&rdquo;), a copy of which shall remain attached to the minutes recording the present
resolution. The 2024 Share Options have a term of ten years as from their issue date.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des
                                                                                                                                                                                                                                                        Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in; width: 50%">(b)&nbsp;&nbsp;<U>Actions
sous-jacentes:</U> Chaque 2024 Share Option donne &agrave; son d&eacute;tenteur le droit de souscrire &agrave; une nouvelle action qui
sera &eacute;mise par la Soci&eacute;t&eacute;. Les nouvelles actions &agrave; &eacute;mettre lors de l&rsquo;exercice des 2024 Share
Options auront les m&ecirc;mes droits et avantages, et seront &agrave; tous &eacute;gards pari passu, en ce compris en ce qui concerne
les droits aux dividendes et autres distributions, avec les actions existantes et en circulation de la Soci&eacute;t&eacute; au moment
de leur &eacute;mission, et auront droit aux dividendes et autres distributions pour lesquelles la date d&rsquo;enregistrement ou la
date d&rsquo;&eacute;ch&eacute;ance tombe &agrave;, ou apr&egrave;s la date d&rsquo;&eacute;mission des nouvelles actions.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%">(b)&nbsp;&nbsp;<U>Underlying
    shares:</U> Each 2024 Share Option shall entitle the holder thereof to subscribe for one new share to be issued by the Company. The
    new shares to be issued at the occasion of the exercise of the 2024 Share Options shall have the same rights and benefits as, and
    rank pari passu in all respects, including as to entitlements to dividends and other distributions, with the existing and outstanding
    shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which
    the relevant record date or due date falls on or after the date of issue of the new shares.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">(c)&nbsp;&nbsp;<U>Suppression
du droit de pr&eacute;f&eacute;rence en faveur des Participants S&eacute;lectionn&eacute;s:</U> L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale
des actionnaires d&eacute;cide, conform&eacute;ment &agrave; l&rsquo;article 7:191 du Code des soci&eacute;t&eacute;s et des associations,
de supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants
de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription en circulation (share options)
de la Soci&eacute;t&eacute;, en faveur des Participants S&eacute;lectionn&eacute;s, et d&rsquo;approuver la possibilit&eacute; pour la
Soci&eacute;t&eacute; d&rsquo;octroyer les 2024 Share Options aux Participants S&eacute;lectionn&eacute;s, comme expliqu&eacute; plus
en d&eacute;tail dans le rapport du conseil d&rsquo;administration vis&eacute; au point 1.(a) de l&rsquo;ordre du jour et dans les termes
et conditions du Plan.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="text-indent: -0.25in; margin-left: 0in; margin-top: 0in; margin-bottom: 0in">(c)&nbsp;&nbsp;<U>Dis-application
                                            of the preferential subscription right for the benefit of the Selected Participants:</U>
                                            The general shareholders&rsquo; meeting resolves, in accordance with article 7:191 of the
                                            Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the
                                            preferential subscription right of the existing shareholders of the Company and, insofar
                                            as required, of the holders of outstanding subscription rights (share options) of the Company,
                                            for the benefit of the Selected Participants, and to approve the possibility for the Company
                                            to grant the 2024 Share Options to the Selected Participants, as further explained in the
                                            report of the board of directors referred to in item 1.(a) of the agenda and the terms and
                                            conditions of the Plan.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;<U>Confirmation
    de la souscription de 2024 Share Options par la Soci&eacute;t&eacute;:</U> L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des
    actionnaires d&eacute;cide d&rsquo;approuver et de confirmer que la Soci&eacute;t&eacute; sera en mesure de souscrire aux 2024 Share
    Options, en vue de cr&eacute;er un pool de 2024 Share Options disponible pour des octrois ult&eacute;rieurs aux Participants
    S&eacute;lectionn&eacute;s. La Soci&eacute;t&eacute; ne peut cependant pas exercer les 2024 Share Options pour son compte
    propre.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;<U>Confirmation of the
subscription of 2024 Share Options by the Company:</U> The general shareholders&rsquo; meeting resolves to approve and confirm that the Company
will be able to subscribe for the 2024 Share Options, with a view to creating a pool of outstanding 2024 Share Options available for further
grants to Selected Participants. The Company may not, however, exercise the 2024 Share Options for its own account.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in">(e)&nbsp;&nbsp;<U>Augmentation
    de capital conditionnelle et &eacute;mission de nouvelles actions:</U> L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires
    d&eacute;cide, sous r&eacute;serve et dans la mesure de l&rsquo;exercice des 2024 Share Options, d&rsquo;augmenter le capital de
    la Soci&eacute;t&eacute; et d&rsquo;&eacute;mettre le nombre appropri&eacute; de nouvelles actions pouvant &ecirc;tre &eacute;mises
    lors de l&rsquo;exercice des 2024 Share Options. Sous r&eacute;serve et conform&eacute;ment aux dispositions du Plan, lors de l&rsquo;exercice
    des 2024 Share Options et de l&rsquo;&eacute;mission de nouvelles actions, le montant total du prix d&rsquo;exercice des 2024 Share
    Options sera affect&eacute; (le cas &eacute;ch&eacute;ant, apr&egrave;s conversion dans la devise du capital de la Soci&eacute;t&eacute;,
    sur la base du taux de change USD/EUR publi&eacute; par la Banque centrale europ&eacute;enne, comme pr&eacute;vu &agrave; la section
    5.2 du Plan) au capital de la Soci&eacute;t&eacute;. Dans la mesure o&ugrave; le montant du prix d&rsquo;exercice des 2024 Share
    Options, par action &agrave; &eacute;mettre lors de l&rsquo;exercice des 2024 Share Options, exc&egrave;de le pair comptable des
    actions de la Soci&eacute;t&eacute; existantes alors imm&eacute;diatement avant l&rsquo;&eacute;mission des nouvelles actions concern&eacute;es,
    une partie du prix d&rsquo;exercice, par action &agrave; &eacute;mettre lors de l&rsquo;exercice des 2024 Share Options, &eacute;gale
    &agrave; ce pair comptable sera comptabilis&eacute;e en capital, le solde &eacute;tant comptabilis&eacute; en prime d&rsquo;&eacute;mission.
    Suite &agrave; l&rsquo;augmentation de capital et &agrave; l&rsquo;&eacute;mission de nouvelles actions, chaque action nouvelle et
    existante repr&eacute;sentera la m&ecirc;me fraction du capital de la Soci&eacute;t&eacute;.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(e)&nbsp;&nbsp;<U>Conditional
    capital increase and issue of new shares:</U> The general shareholders&rsquo; meeting resolves, subject to, and to the extent of
    the exercise of the 2024 Share Options, to increase the Company&rsquo;s share capital and to issue the relevant number of new shares
    issuable upon the exercise of the 2024 Share Options. Subject to, and in accordance with, the provisions of the Plan, upon exercise
    of the 2024 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2024 Share Options will be allocated
    to (as the case may be, following conversion into the Company&rsquo;s share capital currency, on the basis of the relevant USD/EUR
    exchange ratio as shall be published by the European Central Bank, as provided for in section 5.2 of the Plan) the share capital
    of the Company. To the extent that the amount of the exercise price of the 2024 Share Options, per share to be issued upon exercise
    of the 2024 Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to
    the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2024 Share Options,
    equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following
    the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the share capital
    of the Company.</TD></TR>
  </TABLE>




<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des
                                                                                                                                                                                                                                                        Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;<U>Prime
    d&rsquo;&eacute;mission:</U> Toute prime d&rsquo;&eacute;mission qui sera comptabilis&eacute;e en relation avec les 2024 Share Options
    sera comptabilis&eacute;e sur un compte indisponible au passif du bilan de la Soci&eacute;t&eacute; dans ses capitaux propres, et
    le compte sur lequel la prime d&rsquo;&eacute;mission sera comptabilis&eacute;e constituera, au m&ecirc;me titre que le capital de
    la Soci&eacute;t&eacute;, la garantie des tiers et, sauf possibilit&eacute; de capitalisation de ces r&eacute;serves, ne pourra &ecirc;tre
    r&eacute;duit ou supprim&eacute; que par une d&eacute;cision de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires
    statuant dans les conditions requises pour la modification des statuts de la Soci&eacute;t&eacute;.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Issue
    premium</U>: Any issue premium that will be booked in connection with the 2024 Share Options shall be accounted for on a non-distributable
    account on the liabilities side of the Company&rsquo;s balance sheet under its net equity, and the account on which the issue premium
    will be booked shall, like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful
    resolution of the general shareholders&rsquo; meeting passed in the manner required for an amendments to the Company&rsquo;s articles
    of association.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; border-right: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-right: Black 1pt solid; padding-left: 0.5in; padding-right: 5.4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;<U>Procurations:</U> Le conseil d&rsquo;administration est autoris&eacute; &agrave; mettre en &oelig;uvre et &agrave; ex&eacute;cuter les r&eacute;solution
    adopt&eacute;es par l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires en rapport avec les 2024 Share Options, et &agrave;
    prendre toutes les mesures et &agrave; accomplir toutes les formalit&eacute;s requises en vertu du Plan, des statuts de la Soci&eacute;t&eacute;
    et de la loi applicable afin d&rsquo;&eacute;mettre ou transf&eacute;rer les actions lors de l&rsquo;exercice des 2024 Share Options.
    En outre, chaque administrateur de la Soci&eacute;t&eacute;, Joe Sollee et Ron Kalfus, chacun agissant individuellement et avec possibilit&eacute;
    de subd&eacute;l&eacute;gation et pouvoir de subrogation, auront le pouvoir, lors de l&rsquo;exercice des 2024 Share Options, (i)
    de proc&eacute;der &agrave; la constatation (A) de l&rsquo;augmentation de capital et de l&rsquo;&eacute;mission de nouvelles actions
    r&eacute;sultant de cet exercice, (B) de l&rsquo;allocation du capital et (le cas &eacute;ch&eacute;ant) de la prime d&rsquo;&eacute;mission,
    et (C) de la modification des statuts de la Soci&eacute;t&eacute; afin de refl&eacute;ter le nouveau capital et nombre d&rsquo;actions
    en circulation suite &agrave; l&rsquo;exercice des 2024 Share Options, (ii) de signer et remettre, au nom de la Soci&eacute;t&eacute;,
    la documentation Euroclear, Computershare, Nasdaq, bancaire et/ou autre pertinente, le registre des actions et tous les autres documents
    n&eacute;cessaires en relation avec l&rsquo;&eacute;mission et la d&eacute;livrance des actions aux Participant S&eacute;lectionn&eacute;s
    concern&eacute;s et l&rsquo;admission de ces actions &agrave; la cotation et &agrave; la n&eacute;gociation, et (iii) faire tout
    ce qui peut &ecirc;tre n&eacute;cessaire ou utile (y compris, mais sans s&rsquo;y limiter, la pr&eacute;paration et l&rsquo;ex&eacute;cution
    de tous les documents et formulaires) pour l&rsquo;admission des actions &eacute;mises lors de l&rsquo;exercice des 2024 Share Options
    &agrave; la n&eacute;gociation sur Nasdaq (ou tout autre march&eacute; sur lequel les actions de la Soci&eacute;t&eacute; seront
    n&eacute;goci&eacute;es &agrave; ce moment).</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.5in; padding-right: 4pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;<U>Powers
    of attorney:</U> The board of directors is authorised to implement and execute the resolutions passed by the general shareholders&rsquo;
    meeting in connection with the 2024 Share Options, and to take all steps and carry out all formalities that shall be required by
    virtue of the Plan, the Company&rsquo;s articles of association and applicable law in order to issue or transfer the shares upon
    exercise of the 2024 Share Options. Furthermore, each of the Company&rsquo;s directors, Joe Sollee and Ron Kalfus, each such person
    acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the
    2024 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise,
    (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company&rsquo;s articles
    of association in order to reflect the new share capital and number of outstanding shares following the exercise of the 2024 Share
    Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Computershare, Nasdaq, bank and/or other documentation,
    the share register and all other necessary documents in connection with the issuance and delivery of the shares to the Selected Participants
    concerned and the admission to listing and trading of such shares, and (iii) to do whatever may be necessary or useful (including
    but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise
    of the 2024 Share Options to trading on Nasdaq (or such other markets on which the Company&rsquo;s shares will be trading at that
    time).</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des
                                                                                                                                                                                                                                                        Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&#9658;</I></B></FONT><B><I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Instruction de vote</U></FONT></I></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Voting instruction</U></FONT></I></B>:</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Pour / For</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Contre / Against</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Abstention</I></FONT></TD></TR>
  </TABLE>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt"><FONT STYLE="font-size: 10pt">3. &nbsp;&nbsp;&nbsp;<U>Communication des rapports &ndash; Warrants d&rsquo;Exact Sciences</U></FONT></TD>
    <TD STYLE="padding-right: 4pt; width: 50%; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;3.&nbsp;&nbsp;&nbsp;
<U>Submission of reports &ndash; Exact Sciences Warrants</U></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 0.25in; text-align: justify; width: 50%">Communication et discussion sur:</TD>
    <TD STYLE="padding-left: 0.25in; text-align: justify; text-indent: 0pt; width: 50%">Submission of and discussion on:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-left: 12.6pt; text-indent: -0.1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;le
    rapport du conseil d&rsquo;administration de la Soci&eacute;t&eacute;, pr&eacute;par&eacute; conform&eacute;ment aux articles 7:180,
    7:191 et 7:193 du Code des soci&eacute;t&eacute;s et associations, concernant la proposition d&rsquo;&eacute;mettre, en faveur de
    Genomic Health, Inc. (une filiale d&rsquo;Exact Sciences Corporation d&eacute;nomm&eacute;e ci-apr&egrave;s &ldquo;<B>Exact
    Sciences</B>&rdquo;) 1.000.000 de nouveaux droits de souscription pour actions de la Soci&eacute;t&eacute; (les &ldquo;<B>Warrants
    d&rsquo;Exact Sciences</B>&rdquo;), et de supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de
    pr&eacute;f&eacute;rence des actionnaires existants de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs
    de droits de souscription en circulation (share options) de la Soci&eacute;t&eacute;, en faveur d&rsquo;Exact Sciences ; et</TD>
    <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;the
    report of the board of directors of the Company, prepared in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies
    and Associations Code, in relation to the proposal to issue, for the benefit of Genomic Health, Inc. (a subsidiary of Exact Sciences
    Corporation referred to herein as &ldquo;<B>Exact Sciences</B>&rdquo;) 1,000,000 new subscription rights for shares of the Company
    (the &ldquo;<B>Exact Sciences Warrants</B>&rdquo;), and to dis-apply, in the interest of the Company, the preferential subscription
    right of the Company&rsquo;s existing shareholders and, insofar as required, of the holders of subscription rights (share options) of the
    Company, for the benefit of Exact Sciences; and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 30.25pt; text-align: justify; text-indent: -0.25in"></TD>
    <TD STYLE="padding-left: 33.75pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(b)&nbsp;&nbsp;&nbsp;le
    rapport du commissaire de la Soci&eacute;t&eacute;, pr&eacute;par&eacute; conform&eacute;ment aux articles 7:180, 7:191 et 7:193
    du Code des soci&eacute;t&eacute;s et des associations, concernant la proposition d&rsquo;&eacute;mettre en faveur d&rsquo;Exact Sciences 1.000.0000
    de Warrants d&rsquo;Exact Sciences, et de supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence
    des actionnaires existants de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription
    en circulation (share options) de la Soci&eacute;t&eacute;, en faveur d&rsquo;Exact Sciences.<TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;the
                                            report of the Company&rsquo;s statutory auditor, prepared in accordance with articles 7:180, 7:191
                                            and 7:193 of the Belgian Companies and Associations Code, in relation to the proposal to
                                            issue for the benefit of Exact Sciences 1,000,000 Exact Sciences Warrants, and to dis-apply,
                                            in the interest of the Company, the preferential subscription right of the Company&rsquo;s existing
                                            shareholders and, insofar as required, of the holders of subscription rights (share options)
                                            of the Company, for the benefit of Exact Sciences.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 30.25pt; text-align: justify; text-indent: -0.25in"></TD>
    <TD STYLE="padding-left: 33.75pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">4.&nbsp;&nbsp;<U>Proposition d&rsquo;&eacute;mettre
1.000.000 de Warrants d&rsquo;Exact Sciences</U></TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;&nbsp;4.&nbsp;&nbsp; <U>Proposal to issue 1,000,000
Exact Sciences Warrants</U></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;<U>Proposition de r&eacute;solution</U></I></B>:</FONT></TD>
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;&nbsp;&#9658; &nbsp;&nbsp;<U>Proposed resolution</U></I></B>:</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify; text-indent: -0.1pt">L&rsquo;assembl&eacute;e
                                                                                       g&eacute;n&eacute;rale des actionnaires d&eacute;cide d&rsquo;approuver l&rsquo;&eacute;mission de 1.000.000 de nouveaux droits de
                                                                                       souscription pour actions de la Soci&eacute;t&eacute;, d&eacute;nomm&eacute; les &ldquo;Warrants d&rsquo;Exact Sciences&rdquo;, et
                                                                                       de supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires
                                                                                       existants de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription en circulation
                                                                                       (share options) de la Soci&eacute;t&eacute;, en faveur des d&rsquo;Exact Sciences. A cette fin, l&rsquo;assembl&eacute;e
                                                                                       g&eacute;n&eacute;rale des actionnaires d&eacute;cide de ce qui suit :</P>
</TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify; text-indent: -0.1pt">The general shareholders&rsquo;
meeting resolves to approve the issuance of 1,000,000 new subscription rights for shares of the Company, called the &ldquo;Exact Sciences
Warrants&rdquo;, and to dis-apply, in the interest of the Company, the preferential subscription right of the Company&rsquo;s existing shareholders
and, insofar as required, of the holders of outstanding subscription rights (share options) of the Company, for the benefit of Exact Sciences.
To this end, the general shareholders&rsquo; meeting resolves as follows:</P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%">(a)&nbsp;&nbsp;<U>Termes
    et conditions des droits de souscription:</U> Les termes et conditions des Warrants d&rsquo;Exact Sciences seront conformes &agrave;
    l&rsquo;Annexe A du rapport du conseil d&rsquo;administration vis&eacute; au point 3.(a) de l&rsquo;ordre du jour (aux fins de la
    pr&eacute;sente r&eacute;solution, le &ldquo;<B>Les Termes et Conditions des Warrants d&rsquo;Exact Sciences</B>&rdquo;), dont une
    copie restera jointe au proc&egrave;s-verbal constatant la pr&eacute;sente r&eacute;solution. Les principaux termes et conditions
    des Warrants d&rsquo;Exact Sciences peuvent, &agrave; titre d&rsquo;information, &ecirc;tre r&eacute;sum&eacute;s comme suit :<TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%">(a)&nbsp;&nbsp;<U>Terms
                                            and conditions of the subscription rights</U>: The terms and conditions of the Exact Sciences
                                            Warrants will be in accordance with Annex A of the report of the board of directors referred
                                            to in item 3.(a) of the agenda (for the purposes of this resolution, the &ldquo;<B>Exact
                                            Sciences Warrants Terms and Conditions</B>&rdquo;), a copy of which will remain attached
                                            to the minutes recording the present resolution. The main terms and conditions of the Exact
                                            Sciences Warrants can, for information purposes, be summarised as follows:</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD><TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Droit
de souscrire &agrave; une action ordinaire</I> : Chaque Warrant d&rsquo;Exact Sciences permet &agrave; son d&eacute;tenteur de souscrire
&agrave; une (1) action ordinaire de la Soci&eacute;t&eacute; &agrave; &eacute;mettre par la Soci&eacute;t&eacute;.</TD><TD STYLE="margin-left: -0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Right
to subscribe for one ordinary share</I>: Each Exact Sciences Warrant entitles the holder to subscribe for one (1) ordinary share of the
Company to be issued by the Company.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%">
                                                                                                                                                                   <P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;<I>Prix
d&rsquo;exercice</I>: Le prix d&rsquo;exercice des Warrants d&rsquo;Exact Sciences (c&rsquo;est-&agrave;-dire le prix &agrave; payer en num&eacute;raire pour
souscrire &agrave; une nouvelle action de la Soci&eacute;t&eacute; lorsqu&rsquo;un Warrant Exact Sciences est exerc&eacute;) sera de USD 5,265.
Le prix d&rsquo;exercice est sujet &agrave; d&rsquo;&eacute;ventuels ajustements habituels &agrave; la baisse en cas de certaines actions dilutives
de la Soci&eacute;t&eacute;;</P>
                                                                                                                                                                   <P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iii)&nbsp;&nbsp;&nbsp;<I>Dur&eacute;e: </I>Les Warrants d&rsquo;Exact Sciences auront une dur&eacute;e commen&ccedil;ant &agrave; partir de leur &eacute;mission et se terminant
le 22 ao&ucirc;t 2028 (inclus).</P>
                                                                                                                                                                   <P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iv)<I>&nbsp;&nbsp;Possibilit&eacute;
                                            d&rsquo;exercice: </I>L&rsquo;exercice des Warrants d&rsquo;Exact Sciences sera soumis aux
                                            termes et conditions contenus dans les Termes et Conditions des Warrants d&rsquo;Exact Sciences.
                                            Les Warrants d&rsquo;Exact Sciences peuvent &ecirc;tre exerc&eacute;s &agrave; partir de
                                            leur &eacute;mission et jusqu&rsquo;&agrave; la fin de leur dur&eacute;e, &agrave; condition
                                            qu&rsquo;un nombre de Warrants d&rsquo;Exact Sciences avec un prix d&rsquo;exercice global
                                            d&rsquo;au moins USD 250.000 soit exerc&eacute; par leur d&eacute;tenteur.</P>
                                                                                                                                                                   <P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-size: 10pt">(v)<I>&nbsp;&nbsp;&nbsp;Cessibilit&eacute;: </I>A moins que la Soci&eacute;t&eacute; autorise explicitement la cession des Warrants d&rsquo;Exact Sciences, les Warrants d&rsquo;Exact
Sciences ne peuvent pas &ecirc;tre c&eacute;d&eacute;s par leur d&eacute;tenteur. En outre, les Warrants d&rsquo;Exact Sciences ne seront
pas admis &agrave; la cotation ou &agrave; la n&eacute;gociation.</FONT></P></TD>
    <TD STYLE="padding-left: 53.2pt; text-align: justify; text-indent: -0.5in; width: 50%">

<P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;<I>Exercise price:</I>
The exercise price of the Exact Sciences Warrants (i.e., the price to be paid in cash to subscribe for one new share in the Company when
an Exact Sciences Warrant is exercised) will be USD 5.265. The exercise price is subject to potential customary downward adjustments
in the case of certain dilutive actions of the Company.</P>
<P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iii)<I>&nbsp;&nbsp;Term:</I> The Exact
Sciences Warrants will have a term starting as from their issuance and ending on (and including) August 22, 2028.</P>
<P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iv)&nbsp;<I>&nbsp;Exercisability: </I>The exercise
of the Exact Sciences Warrants will be subject to the terms and conditions contained in the Exact Sciences Warrants Terms and Conditions.
The Exact Sciences Warrants may be exercised as from their issuance and until the end of their term, provided that a number of Exact
Sciences Warrants with an aggregate exercise price of at least USD 250,000 are exercised by the holder thereof.<I><BR></I></P>
<P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(v)&nbsp;<I>&nbsp;&nbsp;Transferability:
</I>Except if the Company were to explicitly allow a transfer of the Exact Sciences Warrants, the Exact Sciences Warrants cannot be transferred
by the holder. Furthermore, the Exact Sciences Warrants will not be admitted to listing or trading.</p></TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt"><P STYLE="margin-left: 0in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-decoration: none">(b)&nbsp;&nbsp;&nbsp;</FONT><U>Actions
sous-jacentes:</U> Chaque Warrant d&rsquo;Exact Sciences donnera &agrave; son d&eacute;tenteur le droit de souscrire &agrave; une
nouvelle action &agrave; &eacute;mettre par la Soci&eacute;t&eacute;. Les nouvelles actions &agrave; &eacute;mettre lors de l&rsquo;exercice
des Warrants d&rsquo;Exact Sciences auront les m&ecirc;mes droits et avantages, et seront &agrave; tous &eacute;gards pari passu, y compris
en ce qui concerne les droits aux dividendes et autres distributions, avec les actions existantes et en circulation de la Soci&eacute;t&eacute;
au moment de leur &eacute;mission, et auront droit aux dividendes et autres distributions pour lesquelles la date d&rsquo;enregistrement
ou la date d&rsquo;&eacute;ch&eacute;ance tombe &agrave;, ou apr&egrave;s leur date d&rsquo;&eacute;mission.</P>
</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(b)&nbsp;&nbsp;&nbsp;<U>Underlying
  shares</U>: Each Exact Sciences Warrant will entitle its holder to subscribe for one new share to be issued by the Company. The new
  shares to be issued upon exercise of the Exact Sciences Warrants shall have the same rights and benefits as, and rank pari passu in
  all respects including as to entitlement to dividends and other distributions, with the existing and outstanding shares of the Company
  at the moment of their issuance and will be entitled to dividends and other distributions in respect of which the relevant record date
  or due date falls on or after the date of their issuance.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt"><P STYLE="margin-left: 0in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-decoration: none">(c)&nbsp;&nbsp;&nbsp;</FONT><U>Suppression
                                            du droit de pr&eacute;f&eacute;rence en faveur d&rsquo;Exact Sciences:</U> L&rsquo;assembl&eacute;e
                                            g&eacute;n&eacute;rale des actionnaires d&eacute;cide, conform&eacute;ment aux articles 7:191
                                            et 7:193 du Code des soci&eacute;t&eacute;s et des associations, de supprimer, dans l&rsquo;int&eacute;r&ecirc;t
                                            de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants
                                            de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs actuels
                                            de droits de souscription (share options) de la Soci&eacute;t&eacute;, en faveur d&rsquo;Exact
                                            Sciences, comme expliqu&eacute; dans le rapport du conseil d&rsquo;administration vis&eacute; au
                                            point 3.(a) de l&rsquo;ordre du jour.</P></TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0pt; text-align: justify; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-decoration: none">(c)&nbsp;&nbsp;&nbsp;</FONT><U>Dis-application
                                            of the preferential subscription right for the benefit of Exact Sciences:</U> The general
                                            shareholders&rsquo; meeting resolves, in accordance with articles 7:191 and 7:193 of the Belgian
                                            Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential
                                            subscription right of existing shareholders of the Company and, insofar as required, of the
                                            holders of subscription rights (share options) of the Company, for the benefit of Exact Sciences,
                                            as explained in the report of the board of directors referred to in item 3.(a) of the agenda.</P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des
                                                                                                                                                                                                                                                        Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%"><P STYLE="margin-left: 0in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;&nbsp;<U>Augmentation
de capital conditionnelle et &eacute;mission de nouvelles actions:</U> L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires d&eacute;cide,
sous r&eacute;serve et dans la mesure de l&rsquo;exercice des Warrants d&rsquo;Exact Sciences, d&rsquo;augmenter le capital de la Soci&eacute;t&eacute;
et d&rsquo;&eacute;mettre le nombre appropri&eacute; de nouvelles actions pouvant &ecirc;tre &eacute;mises lors de l&rsquo;exercice des Warrants d&rsquo;Exact
Sciences. Sous r&eacute;serve et conform&eacute;ment aux dispositions des Termes et Conditions des Warrants d&rsquo;Exact Sciences, lors de
l&rsquo;exercice des Warrants d&rsquo;Exact Sciences et de l&rsquo;&eacute;mission de nouvelles actions, le prix d&rsquo;exercice agr&eacute;g&eacute; des Warrants
d&rsquo;Exact Sciences sera comptabilis&eacute; (le cas &eacute;ch&eacute;ant, apr&egrave;s conversion dans la devise du capital de la Soci&eacute;t&eacute;,
sur la base du taux de change USD/EUR publi&eacute; par la Banque centrale europ&eacute;enne, comme pr&eacute;vu &agrave; la section 5.4
des Termes et Conditions des Warrants d&rsquo;Exact Sciences) en tant que capital de la Soci&eacute;t&eacute;. Dans la mesure o&ugrave; le montant
du prix d&rsquo;exercice des Warrants d&rsquo;Exact Sciences, par action &agrave; &eacute;mettre lors de l&rsquo;exercice des Warrants d&rsquo;Exact Sciences,
exc&egrave;de le pair comptable des actions de la Soci&eacute;t&eacute; existantes imm&eacute;diatement avant l&rsquo;&eacute;mission des nouvelles
actions concern&eacute;es, une partie du prix d&rsquo;exercice, par action &agrave; &eacute;mettre lors de l&rsquo;exercice des Warrants d&rsquo;Exact Sciences,
&eacute;gale &agrave; ce pair comptable sera comptabilis&eacute;e en capital, le solde &eacute;tant comptabilis&eacute; en prime d&rsquo;&eacute;mission.
Suite &agrave; l&rsquo;augmentation de capital et &agrave; l&rsquo;&eacute;mission de nouvelles actions, chaque action nouvelle et existante repr&eacute;sentera
la m&ecirc;me fraction du capital de la Soci&eacute;t&eacute;.</P>
</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0pt; text-align: justify; text-indent: 0pt; width: 50%"><P STYLE="margin-left: 0in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;&nbsp;<U>Conditional
capital increase and issue of new shares:</U> The general shareholders&rsquo; meeting resolves, subject to and in the case of the exercise
of the Exact Sciences Warrants, to increase the share capital of the Company and to issue the appropriate number of new shares that may
be issued upon exercise of the Exact Sciences Warrants. Subject to, and in accordance with, the respective provisions of the Exact Sciences
Warrants Terms and Conditions, upon exercise of the Exact Sciences Warrants and the issuance of new shares, the aggregate amount of the
exercise price of the Exact Sciences Warrants will be allocated to (as the case may be, following conversion into the Company&rsquo;s
share capital currency, on the basis of the relevant USD/EUR exchange ratio as shall be published by the European Central Bank, as provided
for in section 5.4 of the Exact Sciences Warrants Terms and Conditions) the share capital of the Company. To the extent that the amount
of the exercise price of the Exact Sciences Warrants, per share to be issued upon exercise of the Exact Sciences Warrants, exceeds the
fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part
of the exercise price, per share to be issued upon exercise of the Exact Sciences Warrants, equal to such fractional value shall be booked
as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of new shares, each
new and existing share shall represent the same fraction of the share capital of the Company.</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(e)&nbsp;&nbsp;&nbsp;<U>Prime
  d&rsquo;&eacute;mission:</U> Toute prime d&rsquo;&eacute;mission qui sera comptabilis&eacute;e en rapport avec les Warrants d&rsquo;Exact Sciences (sur
  exercice des Warrants d&rsquo;Exact Sciences ou autrement) sera comptabilis&eacute;e sur un compte indisponible au passif du bilan de la
  Soci&eacute;t&eacute; dans ses capitaux propres, et le compte sur lequel la prime d&rsquo;&eacute;mission sera comptabilis&eacute;e constituera,
  au m&ecirc;me titre que le capital de la Soci&eacute;t&eacute;, la garantie des tiers et, sauf possibilit&eacute; de capitalisation
  de ces r&eacute;serves, ne pourra &ecirc;tre r&eacute;duit ou supprim&eacute; que par une d&eacute;cision de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale
  des actionnaires statuant dans les conditions requises pour la modification des statuts de la Soci&eacute;t&eacute;.</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="text-decoration: none">(e)&nbsp;&nbsp;&nbsp;</FONT><U>Issue
premium:</U> Any issue premium that will be booked in connection with the Exact Sciences Warrants (whether upon exercise of the Exact
Sciences Warrants, or otherwise) will be accounted for on a non-distributable account on the liabilities side of the Company&rsquo;s
balance sheet under its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as
a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general shareholders&rsquo; meeting
passed in the manner required for an amendments to the Company&rsquo;s articles of association.</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Procurations:</U>
  Le conseil d&rsquo;administration est autoris&eacute; &agrave; mettre en &oelig;uvre et &agrave; ex&eacute;cuter les r&eacute;solutions
  adopt&eacute;s par l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires en rapport avec les Warrants d&rsquo;Exact Sciences, et
  &agrave; prendre toutes les mesures et &agrave; accomplir toutes les formalit&eacute;s qui seront requises en vertu des Termes et
  Conditions des Warrants d&rsquo;Exact Sciences, des statuts de la Soci&eacute;t&eacute;
et des lois applicables afin d&rsquo;&eacute;mettre ou transf&eacute;rer les actions lors de l&rsquo;exercice des Warrants d&rsquo;Exact Sciences. En outre,
chaque administrateur de la Soci&eacute;t&eacute;, Joe Sollee et Ron Kalfus, chacun agissant individuellement et avec possibilit&eacute;
de subd&eacute;l&eacute;gation et pouvoir de subrogation, auront le pouvoir, lors de l&rsquo;exercice des Warrants d&rsquo;Exact Sciences, (i) de
proc&eacute;der &agrave; la constatation (A) de l&rsquo;augmentation de capital et de l&rsquo;&eacute;mission de nouvelles actions r&eacute;sultant
de cet exercice, (B) de la comptabilisation en tant que capital et (le cas &eacute;ch&eacute;ant) prime d&rsquo;&eacute;mission, et (C) de la
modification des statuts de la Soci&eacute;t&eacute; afin de refl&eacute;ter le nouveau capital et nombre d&rsquo;actions en circulation suite
&agrave; l&rsquo;exercice des Warrants d&rsquo;Exact Sciences, (ii) de signer et remettre, au nom de la Soci&eacute;t&eacute;, la documentation Euroclear,
Computershare, Nasdaq, bancaire et/ou autre pertinente, le registre des actions et tous les autres documents n&eacute;cessaires en relation
avec l&rsquo;&eacute;mission et la d&eacute;livrance des actions au b&eacute;n&eacute;ficiaire et l&rsquo;admission de ces actions &agrave; la cotation
et &agrave; la n&eacute;gociation, et (iii) faire tout ce qui peut &ecirc;tre n&eacute;cessaire ou utile (y compris, mais sans s&rsquo;y limiter,
la pr&eacute;paration et l&rsquo;ex&eacute;cution de tous les documents et formulaires) pour l&rsquo;admission des actions &eacute;mises lors de l&rsquo;exercice
des Warrants d&rsquo;Exact Sciences &agrave; la n&eacute;gociation sur le Nasdaq (ou tout autre march&eacute; sur lequel les actions de la Soci&eacute;t&eacute;
seront alors n&eacute;goci&eacute;es &agrave; ce moment).</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Powers
                                            of attorney:</U> The board of directors is authorised to implement and execute the resolutions
                                            adopted by the general shareholders&rsquo; meeting in connection with the Exact Sciences
                                            Warrants, and to take all measures and carry out all formalities that will be required pursuant
                                            to the Exact Sciences Warrants Terms and Conditions, the Company&rsquo;s articles of association
                                            and all applicable laws in order to issue or transfer the shares upon exercise of the Exact
                                            Sciences Warrants. In addition, each director of the Company, Joe Sollee and Ron Kalfus,
                                            each such person acting individually and with the possibility of sub-delegation and power
                                            of subrogation, shall have the power, upon exercise of the Exact Sciences Warrants, (i) to
                                            proceed with the recording of (A) the capital increase and the issue of new shares resulting
                                            from such exercise, (B) the allocation as share capital and (if applicable) as issue premium,
                                            and (C) the amendment of the Company&rsquo;s articles of association to reflect the new share
                                            capital and number of shares outstanding following the exercise of the Exact Sciences Warrants
                                            (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Computershare,
                                            Nasdaq and/or bank documentation, the share register and all other necessary documents in
                                            connection with the issuance and delivery of the shares to the beneficiary and the admission
                                            to listing and trading of such shares, and (iii) to do whatever may be necessary or useful
                                            (including, but not limited to, the preparation and execution of all documents and forms)
                                            for the admission of the shares issued upon exercise of the Exact Sciences Warrants to trading
                                            on Nasdaq (or any other market on which the Company&rsquo;s shares will then be traded).</P>
</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des
                                                                                                                                                                                                                                                        Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt"><B><I>&#9658;</I></B></FONT><B><I> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><U>Instruction de vote</U></FONT></I></B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658; <FONT STYLE="text-transform: uppercase"><U>Voting instruction</U></FONT></I></B>:</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Pour / For</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Contre / Against</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0 Abstention</I></FONT></TD></TR>
  </TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt; width: 50%">5.&nbsp;&nbsp;&nbsp;<U>Communication
    des rapports - Warrants d&rsquo;OrbiMed</U></TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt; width: 50%">&nbsp;&nbsp;5.&nbsp;&nbsp; <U>Submission of reports - OrbiMed Warrants</U></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 0.375in; text-align: justify; text-indent: -13.5pt">Communication et discussion sur:</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 0.375in; text-align: justify; text-indent: -12.8pt">Submission of and discussion on:&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt"><P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;le rapport du
conseil d&rsquo;administration de la Soci&eacute;t&eacute;, pr&eacute;par&eacute; conform&eacute;ment aux articles 7:180, 7:191 et 7:193 du
Code des soci&eacute;t&eacute;s et associations, concernant la proposition d&rsquo;&eacute;mettre, en faveur de OrbiMed Royalty &amp; Credit
Opportunities IV, LP et OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP (ensemble d&eacute;nomm&eacute;s ci-apr&egrave;s &ldquo;<B>OrbiMed</B>&rdquo;)
1.243.060 nouveaux droits de souscription pour actions de la Soci&eacute;t&eacute; (de ces 1.243.060 nouveaux droits de souscription pour
actions, 881.906 nouveaux droits de souscription pour actions &agrave; &eacute;mettre en faveur d&rsquo;OrbiMed Royalty &amp; Credit Opportunities
IV, LP et 361.154 nouveaux droits de souscription pour actions &agrave; &eacute;mettre en faveur d&rsquo;OrbiMed Royalty &amp; Credit Opportunities
IV Offshore, LP), ayant une dur&eacute;e de 5 ans &agrave; partir de leur date d&rsquo;&eacute;mission, (les &ldquo;<B>Warrants d&rsquo;OrbiMed</B>&rdquo;),
et de supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants
de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription en circulation (share options)
de la Soci&eacute;t&eacute;, en faveur d&rsquo;OrbiMed ; et</P>
</TD>
    <TD STYLE="padding-right: 0pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt"><P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;the report of
the board of directors of the Company, prepared in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations
Code, in relation to the proposal to issue, for the benefit of OrbiMed Royalty &amp; Credit Opportunities IV, LP and OrbiMed Royalty &amp;
Credit Opportunities IV Offshore, LP (together referred to herein as &ldquo;<B>OrbiMed</B>&rdquo;) 1,243,060 new subscription rights for
shares of the Company (of those 1,243,060 new subscription rights for shares, 881,906 new subscription rights for shares to be issued
for the benefit of OrbiMed Royalty &amp; Credit Opportunities IV, LP and 361,154 new subscription rights for shares to be issued for the
benefit of OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP), with a term of 5 years as from their issue date (the &ldquo;<B>OrbiMed
Warrants</B>&rdquo;), and to dis-apply, in the interest of the Company, the preferential subscription right of the Company&rsquo;s existing shareholders
and, insofar as required, of the holders of subscription rights (share options) of the Company, for the benefit of OrbiMed; and</P>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt"><P STYLE="margin-left: -0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(b)&nbsp;&nbsp;&nbsp;le rapport du
commissaire de la Soci&eacute;t&eacute;, pr&eacute;par&eacute; conform&eacute;ment aux articles 7:180, 7:191 et 7:193 du Code des soci&eacute;t&eacute;s
et des associations, concernant la proposition d&rsquo;&eacute;mettre en faveur d&rsquo;OrbiMed 1.243.060 Warrants d&rsquo;OrbiMed, et de supprimer, dans
l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants de la Soci&eacute;t&eacute;
et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription en circulation (share options) de la Soci&eacute;t&eacute;,
en faveur d&rsquo;OrbiMed.</P>
</TD>
    <TD STYLE="margin-left: -0.25in; padding-left: 0.375in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;the report of the Company&rsquo;s statutory auditor, prepared in accordance
with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code, in relation to the proposal to issue for the benefit
of OrbiMed 1,243,060 OrbiMed Warrants, and to dis-apply, in the interest of the Company, the preferential subscription right of the Company&rsquo;s
existing shareholders and, insofar as required, of the holders of subscription rights (share options) of the Company, for the benefit
of OrbiMed.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">6.&nbsp;&nbsp;&nbsp;<U>Proposition
    d&rsquo;&eacute;emettre 1.243.060 Warrants d&rsquo;OrbiMed</U>&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;&nbsp;6.&nbsp;&nbsp;<U>Proposal
    to issue 1,243,060 OrbiMed Warrants</U>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt"><B><I>&#9658;&nbsp;&nbsp;<U>Proposition de r&eacute;solution</U></I></B>:</FONT></TD>
    <TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-size: 10pt"><B><I>&nbsp;&nbsp;&#9658; &nbsp;&nbsp;<U>Proposed resolution</U></I></B>:</FONT></TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="font-size: 7pt; border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; text-align: justify; text-indent: -0.1pt">L&rsquo;assembl&eacute;e
g&eacute;n&eacute;rale des actionnaires d&eacute;cide d&rsquo;approuver l&rsquo;&eacute;mission de 1.243.060 nouveaux droits de souscription pour
actions de la Soci&eacute;t&eacute;, ayant une dur&eacute;e de 5 ans &agrave; partir de leur date d&rsquo;&eacute;mission, d&eacute;nomm&eacute;s
les &ldquo;Warrants d&rsquo;OrbiMed&rdquo;, et de supprimer, dans l&rsquo;int&eacute;r&ecirc;t de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence
des actionnaires existants de la Soci&eacute;t&eacute; et, pour autant que de besoin, des d&eacute;tenteurs de droits de souscription
en circulation (share options) de la Soci&eacute;t&eacute;, en faveur de chacun d&rsquo;OrbiMed Royalty &amp; Credit Opportunities IV, LP et
OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP. A cette fin, l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires d&eacute;cide
de ce qui suit :</P>
</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.5pt; padding-left: 0.25in; text-align: justify; text-indent: -0.1pt">The general shareholders&rsquo; meeting resolves to approve the issuance
of 1,243,060 new subscription rights for shares of the Company, with a term of 5 years as from their issue date, called the &ldquo;OrbiMed
Warrants&rdquo;, and to dis-apply, in the interest of the Company, the preferential subscription right of the Company&rsquo;s existing shareholders
and, insofar as required, of the holders of subscription rights (share options) of the Company, for the benefit of each of OrbiMed Royalty
&amp; Credit Opportunities IV, LP and OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP. To this end, the general shareholders&rsquo;
meeting resolves as follows:</TD></TR>
<TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="font-size: 7pt; border-right: Black 1pt solid; padding-right: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;<U>Termes
et conditions des droits de souscription:</U> Les termes et conditions des Warrants d&rsquo;OrbiMed seront conformes &agrave; l&rsquo;annexe A du
rapport du conseil d&rsquo;administration vis&eacute; au point 5.(a) de l&rsquo;ordre du jour (aux fins de la pr&eacute;sente r&eacute;solution,
le &ldquo;Les Termes et Conditions des Warrants d&rsquo;OrbiMed&rdquo;), dont une copie restera jointe au proc&egrave;s-verbal constatant la
pr&eacute;sente r&eacute;solution. Les principaux termes et conditions des Warrants d&rsquo;OrbiMed peuvent, &agrave; titre d&rsquo;information,
&ecirc;tre r&eacute;sum&eacute;s comme suit :</P>
</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(a)&nbsp;&nbsp;&nbsp;<U>Terms
    and conditions of the subscription rights</U>: The terms and conditions of the OrbiMed Warrants will be in accordance with Annex
    A of the report of the board of directors referred to in item 5.(a) of the agenda (for the purposes of this resolution, the &ldquo;OrbiMed
    Warrants Terms and Conditions&rdquo;), a copy of which will remain attached to the minutes recording the present resolution. The main
    terms and conditions of the OrbiMed Warrants can, for information purposes, be summarised as follows:</TD></TR>
</TABLE>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font-size: 7pt; vertical-align: top">
    <TD STYLE="font-size: 7pt; border-right: Black 1pt solid; padding-right: 4pt; padding-left: 13.5pt; text-align: justify; text-indent: -13.5pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font-size: 7pt; padding-right: 4pt; padding-left: 12.8pt; text-align: justify; text-indent: -12.8pt; width: 50%">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Droit
de souscrire &agrave; une action ordinaire:</I> Chaque Warrant d&rsquo;OrbiMed permet &agrave; son d&eacute;tenteur de souscrire &agrave;
une (1) action ordinaire de la Soci&eacute;t&eacute; &agrave; &eacute;mettre par la Soci&eacute;t&eacute;.</P>
                                                                            <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(ii)<I>&nbsp;&nbsp;Prix
                                            d&rsquo;exercice:</I> Le prix d&rsquo;exercice des Warrants d&rsquo;OrbiMed (c&rsquo;est-&agrave;-dire
                                            le prix &agrave; payer en num&eacute;raire pour souscrire &agrave; une nouvelle action de
                                            la Soci&eacute;t&eacute; lorsqu&rsquo;un Warrant d&rsquo;OrbiMed est exerc&eacute;) sera
                                            de USD 2,4134. Le prix d&rsquo;exercice est sujet &agrave; d&rsquo;&eacute;ventuels ajustements
                                            habituels &agrave; la baisse en cas de certaines actions dilutives de la Soci&eacute;t&eacute;.</P>
<P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iii)&nbsp;<I>&nbsp;&nbsp;Prix de souscription:</I> Le prix de souscription des 881.906 Warrants d&rsquo;OrbiMed &agrave; &eacute;mettre en faveur d&rsquo;OrbiMed Royalty &amp; Credit Opportunities
IV, LP sera de USD 1.744.485,56 et le prix de souscription des 361.154 Warrants d&rsquo;OrbiMed &agrave; &eacute;mettre en faveur d&rsquo;OrbiMed
Royalty &amp; Credit Opportunities IV Offshore, LP sera de USD 714.394,11. Le prix d&rsquo;&eacute;mission doit &ecirc;tre pay&eacute; pour
la souscription des Warrants d&rsquo;OrbiMed respectifs par OrbiMed Royalty &amp; Credit Opportunities IV, LP et OrbiMed Royalty &amp; Credit
Opportunities IV Offshore, LP, respectivement. Le prix de souscription sera comptabilis&eacute; en tant que prime d&rsquo;&eacute;mission (conform&eacute;ment
ce qui est indiqu&eacute; au paragraphe (d) ci-dessous).</P>
<P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: 0in"><I></I></P></TD>
  <TD STYLE="width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Right
to subscribe for one ordinary share:</I> Each OrbiMed Warrant entitles its holder to subscribe for one (1) ordinary share of the Company
to be issued by the Company.</P>
                         <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;<I>Exercise price: </I>The exercise price of the OrbiMed Warrants (i.e., the price
to be paid in cash to subscribe for one new share in the Company when an OrbiMed Warrant is exercised) will be USD 2.4134. The exercise
price is subject to potential customary downward adjustments in the case of certain dilutive actions of the Company.</P>
                         <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(iii)&nbsp;&nbsp;<I>Subscription
                         price:</I> The subscription price for the 881,906 OrbiMed Warrants to be issued for the benefit of OrbiMed Royalty
                         &amp; Credit Opportunities IV, LP will be USD 1,744,485.56, and the subscription price for the 361,154 OrbiMed
                         Warrants to be issued for the benefit of OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP will be
                         USD 714,394.11. The subscription price shall be booked as issue premium (in accordance with what is stated in
                         paragraph (d) below).</P>
                         <P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in"></P></TD></TR>
                                                                                            <TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; text-indent: -0.25in; padding-left: 0.75in; padding-right: 4pt">(iv)<I>&nbsp;&nbsp;Dur&eacute;e:</I> Les Warrants d&rsquo;OrbiMed auront une dur&eacute;e de 5 ans &agrave; partir de leur date d&rsquo;&eacute;mission.</TD>
  <TD STYLE="margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(iv)<I>&nbsp;&nbsp;Term:
</I>The OrbiMed Warrants will have a term of 5 years as from their issue date.

</TD></TR>
                                                                                            <TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>

<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(v)&nbsp;&nbsp;<I>Possibilit&eacute;
                                            d&rsquo;exercice:</I> L&rsquo;exercice des Warrants d&rsquo;OrbiMed sera soumis aux termes et conditions contenus
                                            dans les Termes et Conditions des Warrants d&rsquo;OrbiMed. Les Warrants d&rsquo;OrbiMed peuvent &ecirc;tre
                                            exerc&eacute;s &agrave; partir de leur &eacute;mission et jusqu&rsquo;&agrave; la fin de leur dur&eacute;e.<BR></P></TD>
  <TD STYLE="width: 50%"><P STYLE="margin-left: 0.25in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(v)&nbsp;&nbsp;&nbsp;<I>Exercisability:
                         </I>The exercise of the OrbiMed Warrants will be subject to the terms and conditions contained in the OrbiMed
                         Warrants Terms and Conditions. The OrbiMed Warrants may be exercised as from their issuance and until the end
                         of their term.<BR></P></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(vi)&nbsp;&nbsp;<I>Cessibilit&eacute;:</I> Les Warrants OrbidMed et tous les droits qui en d&eacute;coulent sont cessibles, en tout ou en partie, par leur d&eacute;tenteur
  concern&eacute; conform&eacute;ment aux Termes et Conditions des Warrants OrbidMed.<TD STYLE="margin-left: 0.25in; padding-left: 0.75in; text-align: justify; text-indent: -0.25in">(vi)&nbsp;&nbsp;<I>Transferability:
</I>The OrbiMed Warrants and all rights thereunder are transferable, in whole or in part, by the relevant holder in accordance with the
OrbiMed Warrants Terms and Conditions.</TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt; width: 50%"><P STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(b)&nbsp;&nbsp;&nbsp;<U>Actions
sous-jacentes:</U> Chaque Warrant d&rsquo;OrbiMed donnera &agrave; son d&eacute;tenteur le droit de souscrire &agrave; une nouvelle
action &agrave; &eacute;mettre par la Soci&eacute;t&eacute;. Les nouvelles actions &agrave; &eacute;mettre lors de l&rsquo;exercice des
Warrants d&rsquo;OrbiMed auront les m&ecirc;mes droits et avantages, et seront &agrave; tous &eacute;gards pari passu, y compris en ce
qui concerne les droits aux dividendes et autres distributions, avec les actions existantes et en circulation de la Soci&eacute;t&eacute;
au moment de leur &eacute;mission, et auront droit aux dividendes et autres distributions pour lesquelles la date d&rsquo;enregistrement
ou la date d&rsquo;&eacute;ch&eacute;ance tombe &agrave;, ou apr&egrave;s leur date d&rsquo;&eacute;mission.</P>

</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%">(b)&nbsp;&nbsp;&nbsp;<U>Underlying shares:</U> <FONT STYLE="text-decoration: none">Each
  OrbiMed Warrant will entitle its holder to subscribe for one new share to be issued by the Company. The new shares to be issued upon
  exercise of the OrbiMed Warrants shall have the same rights and benefits as, and rank pari passu in all respects including as to entitlements
  to dividends and other distributions, with the existing and outstanding shares of the Company at the moment of their issuance and will
  be entitled to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date
  of their issuance.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-right: 4pt; border-right: Black 1pt solid; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(c)&nbsp;&nbsp;<U>Suppression
  du droit de pr&eacute;f&eacute;rence en faveur d&rsquo;OrbiMed</U>: L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires d&eacute;cide,
  conform&eacute;ment aux articles 7:191 et 7:193 du Code des soci&eacute;t&eacute;s et des associations, de supprimer, dans l&rsquo;int&eacute;r&ecirc;t
  de la Soci&eacute;t&eacute;, le droit de pr&eacute;f&eacute;rence des actionnaires existants de la Soci&eacute;t&eacute; et, pour autant
  que de besoin, des d&eacute;tenteurs de droits de souscription (share options) de la Soci&eacute;t&eacute;, en faveur de chacun d&rsquo;OrbiMed
  Royalty &amp; Credit Opportunities IV, LP et OrbiMed Royalty &amp; Credit Opportunities IV Offshore, LP., comme expliqu&eacute; dans
  le rapport du conseil d&rsquo;administration vis&eacute; au point 5.(a) de l&rsquo;ordre du jour.</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="margin-left: -0.5in; padding-left: 0.5in; text-align: justify; text-indent: -0.25in">(c)&nbsp;&nbsp;&nbsp;<U>Dis-application
of the preferential subscription right for the benefit of OrbiMed:</U> The general shareholders&rsquo; meeting resolves, in accordance
with articles 7:191 and 7:193 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential
subscription right of the existing shareholders of the Company and, insofar as required, of the holders of subscription rights (share
options) of the Company, for the benefit of each of OrbiMed Royalty &amp; Credit Opportunities IV, LP and OrbiMed Royalty &amp; Credit
Opportunities IV Offshore, LP, as explained in the report of the board of directors referred to in item 5.(a) of the agenda.</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;&nbsp;<U>Augmentation
de capital conditionnelle et &eacute;mission de nouvelles actions:</U> L&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires d&eacute;cide,
sous r&eacute;serve et dans la mesure de l&rsquo;exercice des Warrants d&rsquo;OrbiMed, d&rsquo;augmenter le capital de la Soci&eacute;t&eacute; et d&rsquo;&eacute;mettre
le nombre appropri&eacute; de nouvelles actions pouvant &ecirc;tre &eacute;mises lors de l&rsquo;exercice des Warrants d&rsquo;OrbiMed. Sous r&eacute;serve
et conform&eacute;ment aux dispositions des Termes et Conditions des Warrants d&rsquo;OrbiMed, lors de l&rsquo;exercice des Warrants d&rsquo;OrbiMed et
de l&rsquo;&eacute;mission de nouvelles actions, le prix d&rsquo;exercice agr&eacute;g&eacute; des Warrants d&rsquo;OrbiMed sera comptabilis&eacute; (le
cas &eacute;ch&eacute;ant, apr&egrave;s conversion dans la devise du capital de la Soci&eacute;t&eacute;, &#9;sur la base du taux de change
USD/EUR publi&eacute; par la Banque centrale europ&eacute;enne, comme pr&eacute;vu &agrave; la section 4(b) des Termes et Conditions des
Warrants d&rsquo;OrbiMed) en tant que capital de la Soci&eacute;t&eacute;. Dans la mesure o&ugrave; le montant du prix d&rsquo;exercice des Warrants
d&rsquo;OrbiMed, par action &agrave; &eacute;mettre lors de l&rsquo;exercice des Warrants d&rsquo;OrbiMed, exc&egrave;de le pair comptable des actions de
la Soci&eacute;t&eacute; existantes imm&eacute;diatement avant l&rsquo;&eacute;mission des nouvelles actions concern&eacute;es, une partie du
prix d&rsquo;exercice, par action &agrave; &eacute;mettre lors de l&rsquo;exercice des Warrants d&rsquo;OrbiMed, &eacute;gale &agrave; ce pair comptable
sera comptabilis&eacute;e en capital, le solde &#9;&eacute;tant comptabilis&eacute; en prime d&rsquo;&eacute;mission. Suite &agrave; l&rsquo;augmentation
de capital et &agrave; l&rsquo;&eacute;mission de nouvelles actions, chaque action nouvelle et existante repr&eacute;sentera la m&ecirc;me fraction
du capital de la Soci&eacute;t&eacute;.</P>
</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: -0.25in">(d)&nbsp;&nbsp;&nbsp;<U>Conditional
capital increase and issue of new shares:</U> The general shareholders&rsquo; meeting resolves, subject to and in the case of the exercise
of the OrbiMed Warrants, to increase the share capital of the Company and to issue the appropriate number of new shares that may be issued
upon exercise of the OrbiMed Warrants. Subject to, and in accordance with, the respective provisions of the OrbiMed Warrants Terms and
Conditions, upon exercise of the OrbiMed Warrants and the issuance of new shares, the aggregate amount of the exercise price of the OrbiMed
Warrants will be allocated to (as the case may be, following conversion into the Company&rsquo;s share capital currency, on the basis
of the relevant USD/EUR exchange ratio as shall be published by the European Central Bank, as provided for in in section 4(b) of the
OrbiMed Warrants Terms and Conditions) the share capital of the Company. To the extent that the amount of the exercise price of the OrbiMed
Warrants, per share to be issued upon exercise of the OrbiMed Warrants, exceeds the fractional value of the then existing shares of the
Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon
exercise of the OrbiMed Warrants, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked
as issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction
of the share capital of the Company.</P>
</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">(e)&nbsp;&nbsp;&nbsp;<U>Prime d&rsquo;&eacute;mission:</U> Toute prime d&rsquo;&eacute;mission qui sera comptabilis&eacute;e en rapport avec les Warrants d&rsquo;OrbiMed (sur exercice des Warrants d&rsquo;OrbiMed
ou autrement) sera comptabilis&eacute;e sur un compte indisponible au passif du bilan de la Soci&eacute;t&eacute; dans ses capitaux propres,
et le compte sur lequel la prime d&rsquo;&eacute;mission sera comptabilis&eacute;e constituera, au m&ecirc;me titre que le capital de la Soci&eacute;t&eacute;,
la garantie des tiers et, sauf possibilit&eacute; de capitalisation de ces r&eacute;serves, ne pourra &ecirc;tre r&eacute;duit ou supprim&eacute;
que par une d&eacute;cision de l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires statuant dans les conditions requises pour la
modification des statuts de la Soci&eacute;t&eacute;.</P>
</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: -0.25in">(e)&nbsp;&nbsp;&nbsp;<U>Issue premium:</U>
Any issue premium that will be booked in connection with the OrbiMed Warrants (whether as subscription price, upon exercise of the OrbiMed
Warrants, or otherwise) will be accounted for on a non-distributable account on the liabilities side of the Company&rsquo;s balance sheet under
its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third
parties and can only be reduced on the basis of a lawful resolution of the general shareholders&rsquo; meeting passed in the manner required
for an amendments to the Company&rsquo;s articles of association.</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; margin-left: -0.5in; padding-left: 0pt; text-align: justify; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Procurations:</U> Le conseil d&rsquo;administration est autoris&eacute; &agrave; mettre en &oelig;uvre et &agrave; ex&eacute;cuter les r&eacute;solutions
adopt&eacute;es par l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires en rapport avec les Warrants d&rsquo;OrbiMed, et
&agrave; prendre toutes les mesures et &agrave; accomplir toutes les formalit&eacute;s qui seront requises en vertu des Termes et Conditions
des Warrants d&rsquo;OrbiMed, des statuts de la Soci&eacute;t&eacute; et des lois applicables afin d&rsquo;&eacute;mettre ou transf&eacute;rer
les actions lors de l&rsquo;exercice des Warrants d&rsquo;OrbiMed. En outre, chaque administrateur de la Soci&eacute;t&eacute;, Joe Sollee
et Ron Kalfus, chacun agissant individuellement et avec possibilit&eacute; de subd&eacute;l&eacute;gation et pouvoir de subrogation,
auront le pouvoir, lors de l&rsquo;exercice des Warrants d&rsquo;OrbiMed, (i) de proc&eacute;der &agrave; la constatation (A) de l&rsquo;augmentation
de capital et de l&rsquo;&eacute;mission de nouvelles actions r&eacute;sultant de cet exercice, (B) de la comptabilisation en tant que
capital et (le cas &eacute;ch&eacute;ant) prime d&rsquo;&eacute;mission, et (C) de la modification des statuts de la Soci&eacute;t&eacute;
afin de refl&eacute;ter le nouveau capital et nombre d&rsquo;actions en circulation suite &agrave; l&rsquo;exercice des Warrants d&rsquo;OrbiMed,
(ii) de signer et remettre, au nom de la Soci&eacute;t&eacute;, la documentation Euroclear, Computershare, Nasdaq, bancaire et/ou autre
pertinente, le registre des actions et tous les autres documents n&eacute;cessaires en relation avec l&rsquo;&eacute;mission et la d&eacute;livrance
des actions au b&eacute;n&eacute;ficiaire et l&rsquo;admission de ces actions &agrave; la cotation et &agrave; la n&eacute;gociation,
et (iii) faire tout ce qui peut &ecirc;tre n&eacute;cessaire ou utile (y compris, mais sans s&rsquo;y limiter, la pr&eacute;paration
et l&rsquo;ex&eacute;cution de tous les documents et formulaires) pour l&rsquo;admission des actions &eacute;mises lors de l&rsquo;exercice
des Warrants d&rsquo;OrbiMed &agrave; la n&eacute;gociation sur le Nasdaq (ou tout autre march&eacute; sur lequel les actions de la Soci&eacute;t&eacute;
seront alors n&eacute;goci&eacute;es &agrave; ce moment).</P>
</TD>
  <TD STYLE="padding-left: 0.5in; text-align: justify; text-indent: -0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: -0.25in">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Powers of attorney:</U>
The board of directors is authorised to implement and execute the resolutions adopted by the general shareholders&rsquo; meeting in connection
with the OrbiMed Warrants, and to take all measures and carry out all formalities that will be required pursuant to the OrbiMed Warrants
Terms and Conditions, the Company&rsquo;s articles of association and all applicable laws in order to issue or transfer the shares upon exercise
of the OrbiMed Warrants. In addition, each director of the Company, Joe Sollee and Ron Kalfus, each such person acting individually and
with the possibility of sub-delegation and power of subrogation, shall have the power, upon exercise of the OrbiMed Warrants, (i) to proceed
with the recording of (A) the capital increase and the issue of new shares resulting from such exercise, (B) the allocation as share capital
and (if applicable) as issue premium, and (C) the amendment of the Company&rsquo;s articles of association to reflect the new share capital
and number of shares outstanding following the exercise of the OrbiMed Warrants (ii) to sign and deliver, on behalf of the Company, the
relevant Euroclear, Computershare, Nasdaq and/or bank documentation, the share register and all other necessary documents in connection
with the issuance and delivery of the shares to the beneficiary and the admission to listing and trading of such shares, and (iii) to
do whatever may be necessary or useful (including, but not limited to, the preparation and execution of all documents and forms) for the
admission of the shares issued upon exercise of the OrbiMed Warrants to trading on Nasdaq (or any other market on which the Company&rsquo;s
shares will then be traded).</P></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658;
    <FONT STYLE="text-transform: uppercase"><U>Instruction de vote</U></FONT></I></B>:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&#9658;
    <FONT STYLE="text-transform: uppercase"><U>Voting instruction</U></FONT></I></B>:</FONT></TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0
    Pour / For</I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>0
    Contre / Against</I></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: center; border-bottom: Black 1pt solid; font: 11pt Calibri, Helvetica, Sans-Serif; width: 32%"><I>1
    <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abstention</FONT></I></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; width: 50%; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>II.<FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></B>Si
                                                                                                   l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale extraordinaire est ajourn&eacute;e ou suspendue, le mandataire sp&eacute;cial aura les
                                                                                                   pouvoirs de repr&eacute;senter le soussign&eacute; &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale des actionnaires qui sera
                                                                                                   tenue avec le m&ecirc;me ordre du jour, le cas &eacute;ch&eacute;ant:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P></TD>
    <TD STYLE="padding-left: 4pt; width: 50%; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>II.
</B>In case the aforementioned extraordinary general shareholders&rsquo; meeting would be postponed or suspended, the special proxy holder
shall have the power to represent the undersigned at the general shareholders&rsquo; meeting that would be held having the same agenda,
as relevant:&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; oui</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; yes</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; non</FONT></TD>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744; no</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Veuillez remplir la case appropri&eacute;e. Une absence d&rsquo;instruction ou si, pour quelque raison, il y a une absence de clart&eacute; &agrave; propos de l&rsquo;instruction donn&eacute;e, le soussign&eacute; sera suppos&eacute; avoir choisi &ldquo;oui&rdquo;. Veuillez noter qu&rsquo;aux fins de s&rsquo;appliquer &agrave; telle assembl&eacute;e subs&eacute;quente, les titulaires de titres doivent s&rsquo;enregistrer &agrave; nouveau pour cette assembl&eacute;e.</I></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the undersigned shall be deemed to have selected &ldquo;yes&rdquo;. Please note that in order to apply for such subsequent meeting, holders of securities must again register for such meeting.</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Si,
    pendant l'assembl&eacute;e, il y a des modifications &agrave; une proposition de r&eacute;solution ou une nouvelle proposition de
    r&eacute;solution:<SUP>1</SUP></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In case of amendments during the meeting to a proposed resolution or a new proposed resolution:<SUP>1</SUP></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.25in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;le mandataire sp&eacute;cial votera contre la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;the proxy holder shall vote against the amended or new resolution</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.25in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;le mandataire sp&eacute;cial s&rsquo;abstiendra de voter sur la r&eacute;solution modifi&eacute;e ou nouvelle</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;the proxy holder shall abstain from the vote on the amended or new resolution</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; text-indent: -0.25in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;le mandataire sp&eacute;cial votera sur la r&eacute;solution modifi&eacute;e ou nouvelle selon la mani&egrave;re support&eacute;e ou recommand&eacute;e par le conseil d&rsquo;administration de la Soci&eacute;t&eacute;</FONT></TD>
    <TD STYLE="text-indent: -0.25in; padding-left: 0.625in; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;the proxy holder shall vote on the amended or new resolution in the manner supported or recommended by the board of directors of the Company</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><SUP>1
    </SUP>Veuillez cocher tel qu&rsquo;appropri&eacute;. Une absence d&rsquo;instruction sera interpr&eacute;t&eacute;e comme une instruction de
    voter pour la r&eacute;solution modifi&eacute;e ou nouvelle selon la mani&egrave;re support&eacute;e ou recommand&eacute;e par le
    conseil d&rsquo;administration de la Soci&eacute;t&eacute;. </I></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><I><SUP>1</SUP> Please complete as appropriate. An absence of instruction shall
    be tantamount to an instruction to vote for the amended or new resolution as will be supported or recommended by the board of directors
    of the Company.</I></TD></TR>
  </TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>I<FONT STYLE="font-size: 10pt">II.
    </FONT></B><FONT STYLE="font-size: 10pt">Le mandataire sp&eacute;cial est autoris&eacute;, au nom et pour le compte du soussign&eacute;,
    &agrave; signer toutes listes de pr&eacute;sence et proc&egrave;s-verbaux, &agrave; participer &agrave; toutes les d&eacute;lib&eacute;rations,
    &agrave; prendre part au vote sur toutes les d&eacute;cisions ou sujets pouvant, conform&eacute;ment &agrave; cet ordre du jour,
    &ecirc;tre soumis &agrave; l&rsquo;assembl&eacute;e.</FONT></FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>III. </B>The special proxy holder has the power to, in the name of and on behalf of the undersigned, sign all attendance lists and minutes, participate in all deliberations, vote with respect to all decisions or items that can, pursuant to this agenda, be presented to said meeting.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV. </B>Le mandataire sp&eacute;cial est autoris&eacute;, en g&eacute;n&eacute;ral, &agrave; faire tout ce qui semble n&eacute;cessaire et/ou utile pour exercer cette procuration.</FONT> <FONT STYLE="font-size: 10pt"></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Le/la
soussign&eacute;(e) ratifie et approuve par la pr&eacute;sente tous les actes accomplis par le mandataire sp&eacute;cial susmentionn&eacute;.
Le mandataire sp&eacute;cial votera pour le compte du/de la soussign&eacute;(s) conform&eacute;ment aux instructions sp&eacute;cifiques
donn&eacute;es ci-dessus.</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
                                                                                <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">La pr&eacute;sente procuration vaut &eacute;galement
notification conform&eacute;ment aux formalit&eacute;s d&eacute;crites dans l&rsquo;invitation &agrave; l&rsquo;assembl&eacute;e g&eacute;n&eacute;rale
extraordinaire des actionnaires de la Soci&eacute;t&eacute; &agrave; tenir le jeudi 20 juin 2024, &agrave; condition qu&rsquo;elle soit d&ucirc;ment
compl&eacute;t&eacute;e par le soussign&eacute; et re&ccedil;ue par la Soci&eacute;t&eacute; au plus tard &agrave; la Date limite de Notification.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Le soussign&eacute;
confirme que la traduction anglaise de la pr&eacute;sente procuration n&rsquo;est qu&rsquo;une traduction libre en anglais et &agrave; titre informatif
uniquement, et que la version fran&ccedil;aise pr&eacute;vaut sur la version anglaise.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IV. </B>In general, the special proxy holder has the power to do all that appears necessary and/or useful for the exercise of this proxy.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">The undersigned hereby ratifies and
approves all acts carried out by the aforementioned proxy holder. The special proxy holder will vote on behalf of the undersigned in
accordance with the specific instructions given above.</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">The present proxy shall also serve as notification in accordance with the formalities
                                                       described in the notice convening the extraordinary general shareholders&rsquo; meeting of the Company to be held on
                                                       Thursday 20 June 2024, provided it is duly completed by the undersigned and received by the Company at the latest on the
                                                       Notification Deadline.</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                       <P STYLE="margin-top: 0; margin-bottom: 0">The undersigned confirms that the English translation of the present proxy is a free English translation and for information
purposes only, and that the French version shall prevail over the English version.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding-right: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; padding-right: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>BON POUR PROCURATION</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>GOOD FOR PROXY</B></FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">_______________________________2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(date)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">_______________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(nom
/ name)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">_______________________________________
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(signature)</I></FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="text-align: justify; width: 89%; font-size: 10pt"><B>Assembl&eacute;e G&eacute;n&eacute;rale Extraordinaire des
                                                                                                                                                                                                                                                        Actionnaires de MDxHealth SA - Procuration</B></TD><TD STYLE="width: 11%; font-size: 10pt">&nbsp;</TD></TR><TR STYLE="vertical-align: top"><TD STYLE="font-size: 10pt"><B>Extraordinary
                                            General Shareholders&rsquo; Meeting of MDxHealth SA - Proxy</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/15</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-2_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  N 24# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HI
M 02<$''6EH **"0!DG H!R,B@ HHHH **** .7L/$MW=>/=0T%XH!;6T/F(X
M!WDX3KSC^(]JZBO/M'_Y+)K7_7K_ $BKM=3U2TTBU^T7DFQ"=HP,DGT JN5M
MI(S=2,(N4W9(N455T_4;75+47-I*)(R<>A!]"*M4FFG9E1G&<5*+NF%%4]0U
M.UTN$2W4FT,<* ,D_A4MG>07]LEQ;OOC;H:CFC?EOJ.ZO8YZ'Q)=R?$"?0#%
M!]ECA\P. =^=H/7.._I745Y];?\ ):+O_KU_]D6O0:MBB%%%%(H**** "BBB
M@ HHHH **** .7C\2W;_ ! DT Q0?95A\P/@[\[0>N<=_2NHKSZ'_DM$_P#U
MZ_\ LBUZ#39*"BN T261OBWK<9D8H+?(4G@?ZOM7?T-6&G<*Y?P;XDN_$4>H
M-=Q01_9YO+3R@1D<]<DUU%>??"W_ %.L_P#7T/ZT+83W1Z#1112*"BF/-%&<
M/(BGT+ 44 $TT=O!)/*P2.-2S,>P')-><0-KGQ#NYI8KN33="C<HH3AI?\3^
M@]ZZKQP[1^"]4*G!\K'X%@#_ #H\$1I%X,TL(H ,.X^Y))-4M%<EZNQ@O\+X
M($\S3=8OK>[4?+(S C/X8-9Z^/-4\.6][I6N0>=J<  MY .)<]"WMWSWZ=:]
M.KSOQM:PS>/?#.] ?,=5?W <$#]333ON)JVQ#:>"=:\2QK?^(]6GB,OS+;1_
MP ^W1?IBDO/!^N>%(FU#P]JLTZ1#=);2#[P'7CHWY ^E>ET4N9CY48OA;Q#%
MXET9+U%"2@[)HP<[7'].]4?&/BIM AAM;*+S]3NSMACQG';)'?G@"L?X>*(-
M>\36T?$27(VKV'S.*CB47OQGF^T#/V:WS"#V^4?_ !1-%M17=AUOX"U75T%S
MXAUVZ,S\^3"W">WI^0I\OA37O#:_;/#^KSW2Q\M9W/(<>@[9_(^]=_11S,?*
MCR[P9JBZU\2]1U!8FB\ZSR8VZJ1Y8(_,&N^UW18=<L/LTK%&4[HW'\)^G<5Q
MN@V\5K\7]9CA "FW+X'8L8R?U)KT6GS.,E*)G*E&K3=.HKI[GEEI/J7@K6-E
MQ&3 _P!]1]V1?53ZUZ')K5C'I(U(2AH&7*XZL?3ZU6\2S:3%I+_VL%:(_<4?
M?+?[/O7G&G@F%))X[C^SO..WGKZX[9QBM,75YJ#K6M):>3_X8\K!86OA:_U>
MD^:#NU=ZQ_X#-E(-1\6:HTI^6('&X_=C7T'J:[S3M/ATRR2UAR57DD]2>YI-
M+>R>PC.G[/LX' 7M]?>KE>?0HJ'OMW;ZGKPI<CUW/*-:U*[TSXJ7;V%OY]Y-
M"L,"'IN9%Y/L*W1X!O-27SM<\07LMRW)6!MJ(?0 _P" JM!&K_&FX+*"4MMR
MY['8H_J:]#KL;L-*][GF6J:=K_@-5U+3]3FOM-5@)H)R3M!X_+W&*]"TO48=
M6TNVOX,^5.@< ]1ZC\#Q5+Q6BOX3U56&1]F<_I63\/G9/ -LPY*^:0/^!&D]
M5<:T=BGK7B#5=9U]_#OAMQ$T7_'U>'_EGZ@>F.GKFE'PU@D7?=:WJ<MSU,OF
M <^P.3^M<OX'U?5[&"_GL=!DU%YY\RSK)M(/7'0^I/XUUG_"5^*/^A.G_P"_
MW_V--W6Q*:>K,_[?K7@/4[>'5+M]1T2X;8L[_?B/O_AW'2O1%964,I!4C(([
MBO-?$>H>)/$.BRZ=)X2GBWE663S-Q4@YSC'U'XUT0>^LOAHYN$>.\AT]E8-U
M4A2*30TS#O=<UKQAK,^E>')OLMA =L][T+?0_P @.M6%^&46!))KNHM<_P#/
M0,!SZ]S^M7/AE;Q0^#()4 WS2R/(?<-M'Z 5V-#=M$"5]6>8:W=>(?"6EW5C
M?W4E_87,31V]XN1)$^. 3U_4_7M76> YI9_!MA)-(\DA#99V))^8]S4OC2WB
MN?!VIK* 0L)<9[,O(_457^'W_(D:?]'_ /0S1T!*TC$A_P"2T3_]>O\ [(M=
M%XA\,MKTT$BZK=V7E*5VP-@-D]37.P_\EHG_ .O7_P!D6O0:&-*]SQW3/"K7
M/CW4]*_M:\C-O%N^TJW[Q_N<$_C^E=5_PKI_^AEU7_OY_P#7JOH7_)7==_Z]
M_P#XW7H%-MBC%%;3K/[!IUO:&9YO)0)YDARS8[FO(_"5YK$LVH:-HFV&:XG,
MDMVPR(8QQQ[G/^>H]EKSSX6QH!K4FT;S<!2?89_QI+9@UJBRWPV2<>9<Z_J<
MMSU,F_C/T.3^M9\>HZWX$URVLM5O'O\ 2+IMJ3/DLG/J>1C(R,GCI7I5<'\6
M$4^&+9R/F6[4 ^F5:A.[LP:LKHZ2ZTZ:6Y=P9"K'(,;+^N:*TK0YLH"?^>:_
MRHI7*L8?CO\ Y$G5/^N8_P#0A4O@S_D3=*_ZX"M34+"WU2PFLKM"\$HPZ@D9
M&<]1]*6QLH--L8;.V4K!"NU 3G ^M%]+!;6Y8K@?&/\ R/OA7_KK_P"SBN^K
M-OM"L-1U&SO[F)FN+,[H6#D '.>G?I0G8&KFE1112&<!X"_Y&?Q3_P!?(_\
M0GI/&EE>:+X@M/%NGQ&58@$NHQ_=Z9/L0<9[8%==IVA6&E7=Y=6D3)+=OOF)
M<G)R3WZ=36B0&!! (/!![U5]2>72QCZ3XJT;6;99;:^B5B/FBD8*ZGT(-0ZW
MXPTC1;9F:ZCGN,82WA8,S'L..GXU6O\ X>^'+^8RM9&!VY/D.4!_#I5C2?!6
M@Z-,L]M9!IUY625BY7Z9X%&@>\<5X%:^D^(VHRZDACNY;9I)$/\ #N*,!^1%
M=]XBUV/0-.^T-&9)'.R-.Q.._M4L&A:?;ZW/K$<3"]G39(^\X(X[=/X14^H:
M;::I;?9[R$2QYR 3@@^H(IIQYDY;$M2Y6H[GF>EV&H^--8:XO96^SH?WC] H
M_NJ*]+DTNSDTP:?Y*K;!=JJ/X?<>]265C;:=:K;6D2Q1+T4?S]ZL55:I[32V
MG8FA2]GK?7N>=2?VAX4U0A&S&W(S]V1?\:[G2]1CU2P2ZC4J&X*GL13[VPMM
M0A\JZB$B Y'8@^QJ2VMH;.W6"WC"1KT45PTJ,J<G9^Z=]6K&I%77O'!VW_):
M+O\ Z]?_ &1:]!K-30M/377UE8F^W.FQGWG&, =.G85I5U-G*E8R?%'_ "*N
MJ_\ 7K)_Z":R?AQ_R)%G_O2?^AFNFN[6*^LYK6=2T,R%' .,@]:ATO2[31K"
M.RLD*0(254L6ZG)Y-%]+!;6YY_87)^'WBJ[L[Y6&CW[^9#.!D(??Z9P?H#7H
M=OJ%G=0B:WNX)8R,[DD!%+>6-KJ-LUO>6\<\+=4D7(KEY?AEX:DE+B">,?W4
MF./US3NGN*S6Q=U3QKI&FW<-HDIO+F60)Y5M\Y7)ZG'\NM;UQ!'=VLMO*,QR
MH48>Q&#69I'A?1M#.^PLD27&/-8EG_,]/PK8I.W0:OU/,?#NK/X$U.X\/ZWN
M2S>0R6USC*X/?Z'CZ'->@IK&F20^<NHVABQG?YRX_G3M1TNQU:V^SW]K'<1=
M0''0^H/4?A7-'X9>&C+O\BX _N><<?XT[IBLUL8OC?Q4FL:?<Z3H9-RB(9;N
MX3[B(O. >_./Y5TGP^_Y$C3_ */_ .AFM*+P[I-OI4VF06:16LR[9%3(+#W/
M4U9TW3K;2;"*RLT*019VJ6)QDYZFAM6L"3O=G$P_\EHG_P"O7_V1:]!K-70=
M/776UD1-]N9-A?><8QCIT[5I4FQI6/-I;R/PU\6+FYOSY5K?P!4E;[HR%Y)^
MJX_&N[FUG3+>W^T2ZA:I%C.\RK@_3GFDU;1=.UNV%OJ%JDR#E2>"I]B.17/P
M_#3PU#*)#;32 '.UYCC]*>C%9K8Z:PO[;4[*.\LY1+!(,JX[UP_PM_U.L_\
M7T/ZUWEM;06=NEO;0I#"@PJ(N /PJEI&A:?H:SBPB:,3OODRY;)_&E<=M4:5
M<+\5_P#D58/^OM?_ $%J[JL_6=$L=>LUM=0C:2%7#@*Y7D CJ/J:$[,&KJQ:
;L_\ CR@_ZYK_ "HJ1$6.-44850 /I12&?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
